Stockwinners Market Radar for December 13, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:07 EST Cathie Wood's ARK Investment bought 49K shares of Verve Therapeutics today

19:33 EST AST SpaceMobile says on track to deliver first space-based broadband - AST SpaceMobile provides an operational update on the BlueWalker 3, Block 1 BlueBird and next-generation BlueBird programs. CEO Abel Avellan stated: "The achievements to date for BlueWalker 3 validate the design roadmap for our BlueBirds, including deploying and flying the largest-ever commercial communications array in low Earth orbit, a key fundamental and patented technology to deliver space-based cellular broadband directly to unmodified phones. On the back of the successful deployment of BW3's communications array, we look forward to initiating testing with our mobile network operator partners starting early in the first quarter of 2023."

18:32 EST Valens receives 180 days extension from Nasdaq to regain compliance - The Valens Company announced it received an extension of 180 calendar days from the Nasdaq Stock Market to regain compliance with the Nasdaq's minimum $1.00 bid price requirement set forth in Nasdaq Listing Rule 5550 for continued listing on the Nasdaq Capital Market, following the expiration of the initial 180 calendar days period to regain compliance on December 12, 2022. The Nasdaq determination is based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market with the exception of the Bid Price Requirement, and the Company's written notice of its intention to cure the deficiency during the second compliance period by effecting a share consolidation, if necessary. As a result of the extension, the Company now has until June 12, 2023, to regain compliance with the Bid Price Requirement

18:01 EST Arthur J. Gallagher acquires Aviation Insurance Australia for undisclosed amount - Arthur J. Gallagher & Co. announced the acquisition of Brisbane, Queensland-based Aviation Insurance Australia. Terms of the transaction were not disclosed. Founded in 1993, Aviation Insurance Australia is a specialist retail insurance broker serving aviation and aerospace clients throughout the country. Ian Tait and his team will remain in their current location under the direction of Paul Harvey, Managing Director of Specialisms for Gallagher in Australia.

17:48 EST Cytokinetics: FDA panel says benefits of omecamtiv mecarbil do not outweigh risk - Cytokinetics announced that the U.S. FDA Cardiovascular and Renal Drugs Advisory Committee voted 8 to 3 that the benefits of omecamtiv mecarbil do not outweigh its risks for the treatment of heart failure with reduced ejection fraction. "We are disappointed there was not a greater consensus amongst Committee members relating to the benefit-risk of omecamtiv mecarbil, and we maintain our conviction in the strength of evidence supporting its potential benefit for patients suffering from HFrEF," said Robert I. Blum, Cytokinetics' President and CEO. "We continue to believe omecamtiv mecarbil can be a valuable add-on therapy for patients with worsening heart failure who remain at high risk for heart failure events and hospitalization despite treatment with available guideline-directed medical therapy. We plan to engage constructively with FDA as it completes its review of the application for omecamtiv mecarbil."

17:24 EST Assurant finalizes restructuring plan, sees up to $65M in charges - On December 13 Assurant, finalized its plan to realize greater operational efficiencies by continuing to simplify its business portfolio and leverage its global footprint to reduce costs. This includes realigning its organizational structure and talent to support its business strategy. The Company is also accelerating its ongoing real estate consolidation to support work-from-home arrangements given its increasingly hybrid workforce. The Company expects to complete these actions in 2023.The Company expects to incur total pre-tax restructuring charges of approximately $60M to $65M, with approximately $51M to $56M to be incurred in fourth quarter 2022 and the remainder to be incurred in 2023. The total expected range includes approximately $29M to $34M related to severance and employee benefits, and approximately $31M related to real estate exit costs, consisting of lease impairment and abandonment charges. The Company estimates that substantially all of the charges will be cash. The Company expects approximately $55M in gross annualized run rate savings to be realized from these actions by year-end 2024, with more than half expected to be realized in 2023. These savings will partially mitigate the impact of higher labor costs and headwinds from the macroeconomic environment, as well as fund additional investments, including increasing automation, to continue to drive a more efficient cost structure long term. The Company expects to provide its full year 2023 outlook during its fourth quarter 2022 earnings call in February

17:18 EST Celcuity CEO buys $1.5M in common stock - In a regulatory filing, Celcuity disclosed that its CEO Brian Sullivan bought 261K shares of common stock on December 9 in a total transaction size of $1.5M.

17:10 EST Avista announces retirement of CEO Tony Strange - Aveanna Healthcare Holdings announced that its CEO and Director, Tony Strange, is retiring and will depart the company effective December 31. Jeff S. Shaner, Aveanna's long serving Chief Operations Officer, will serve as CEO and Director, effective December 31.

17:01 EST LianBio announces departure of President and Chief Strategy Officer Debra Yu - LianBio announced that Debra Yu, LianBio's, has resigned from the Company, effective January 1, 2023, to pursue other business and professional interests and opportunities. To facilitate her transition, Yu entered into a consulting agreement with LianBio effective January 1, 2023, through June 30, 2023. Yu joined the Company when LianBio was first established in 2019. She has been a valued member of LianBio's executive team and an integral part of LianBio's transformation from an early-stage startup into a late clinical stage biotechnology company.

16:53 EST Fifth Wall Acquisition Corp. III to merge with Mobile Infrastructure Corp. - Fifth Wall Acquisition Corp. III announced that it entered into a definitive business combination agreement with Mobile Infrastructure Corp., one of the largest institutional-quality, mobility-focused parking asset owners in the U.S. Upon the closing of this transaction, the combined company expects to be publicly traded on the New York Stock Exchange under the ticker "BEEP." The business combination values the combined company at a post-money equity valuation of approximately $550M assuming no public shareholders of FWAC exercise their redemption rights. The combined company is expected to have up to approximately $276M in cash at closing, including $275M of cash held in FWAC from its initial public offering on May 27, 2021. The transaction is further supported by a $10M PIPE investment from No Street Capital, an existing MIC shareholder. MIC and FWAC are aligning long-term interests. FWAC's sponsor has agreed to defer a portion of its founder shares in an earn-out with vesting at significant premiums to FWAC's current share price, while MIC's CEO has elected to receive 100% of his 2023 compensation in stock. In addition, a portion of the FWAC Sponsor's founder shares will be cancelled for no consideration. The combined company will have significant insider ownership, and MIC's existing investors are rolling 100% of their equity in the transaction. Additionally, no SPAC warrants have been issued, and as a result, shareholders will benefit from less dilution and a simplified capital structure. The transaction has been unanimously approved by the Boards of Directors of both MIC and FWAC. The transaction is expected to close in the second quarter of 2023, subject to the satisfaction of customary closing conditions, including the approval of shareholders of both parties.

16:48 EST Indonesia Energy announces production updates - Indonesia Energy "announced production updates on its Kruh 27 and Kruh 28 wells. These two back-to-back discovery wells were drilled by IEC during 2022 at its 63,000-acre Kruh Block. Fracture stimulation of the already oil producing Kruh 27 well has been completed, with 80 thousand pounds of proppants having been injected into the sand producing reservoir with the goal of increasing production productivity. A previous fracturing program conducted in IEC's Kruh 26 well brought the original production of 18 barrels of oil per day to a post-fracturing rate of 75 BOPD. IEC anticipates that the stimulation work at Kruh 27 could provide similar production enhancement after the well begins production again expected in January 2023."

16:45 EST Drive Shack to voluntarily delist from the NYSE - Drive Shack announced its intention to voluntarily delist from the NYSE and to deregister its common stock under Section 12 and Section 12 of the Securities Exchange Act of 1934, as amended, and suspend its reporting obligations under Section 15 of the Exchange Act. The Company received a notice that its securities are not in compliance with the continued listing standards of the NYSE, and in response has evaluated its options to remain listed or to go dark and has determined that going dark is the best path for the Company due to expected cost savings and the Company's current inability to realize the traditional benefits of public company status. The Company intends to file an application for its common stock to be quoted on the OTCQX platform, operated by OTC Markets Group Inc. and intends to receive approval in the Q1 of 2023. The Company intends to continue to provide information to its stockholders and to take such actions to enable a trading market in its common stock to exist.

16:36 EST Rubicon announces voluntary delisting from Nasdaq - Rubicon Technology, announced that it has notified The Nasdaq Stock Market of the Company's decision to voluntarily delist its common stock from the Nasdaq Capital Market and its intent to file a Form 25 with the U.S. Securities and Exchange Commission on or about December 23, As a result, the Company expects the delisting of its common stock to become effective on December 30.

16:35 EST BIMI announces reduction of purchase price for the Hospitals to RMB 80K - BIMI International Medical announced its entry into an Amendment to the Stock Purchase Agreement originally entered into as of April 9 for the acquisition of Wuzhou Qiangsheng Hospital. The Amendment provided for the reduction of the purchase price for the Hospitals from RMB 162,000,000 to RMB 80,000,000, including a retroactive decrease in the closing cash payment from RMB 20,000,000 to mil and a retroactive decrease in the closing stock payment from 800,000 shares of the BIMI common stock to 164,000 shares of BIMI common stock. As a result of the amendment, the sellers of the Hospitals agreed to return RMB 20,000.000 in cash and 636.000 shares of the Company's common stock immediately. The sellers agreed that the 2021 and 2022 performance targets as set forth in the April 2021 agreement were not met and therefore, they are not entitled to either of the contingent payments provided for in the original agreement.In light of the forfeited performance payments due to the Hospitals' failure to meet the performance targets for 2021 and 2022, a new 2023 performance target of RMB 5,500,000 in net profit and a corresponding performance payment in the amount of RMB 64,000,000 were added in the Amendment as well as certain post-closing agreements which give the Company the right to sell the Hospitals back to their original owners upon the occurrence of certain events, and the original owners the right to buy the Hospitals back upon occurrence of certain events.All the numbers of shares of the Company's common stock in this press release do not reflect the reverse stock split that be

16:32 EST Franklin Resources raises quarterly dividend by 3.4% to 30c per share - The dividend is payable on January 13, 2023 to stockholders of record holding shares of common stock at the close of business on December 30, 2022.

16:31 EST BTRS Holdings stockholders approve proposed merger with EQT - BTRS Holdings "announced that its stockholders voted to approve the definitive merger agreement with an affiliate of EQT X Fund at a special meeting of the Company's stockholders."

16:23 EST Braze falls 6% to $27.16 after Q3 results and guidance

16:21 EST WD-40 raises quarterly dividend by 6% to 83c per share - The quarterly dividend is payable January 31, 2023 to stockholders of record at the close of business on January 13, 2023.

16:21 EST Matterport appoints Matthew Zinn as chief legal officer - Matterport (MTTR) announced two key executive hires to join the company's leadership team effective immediately. Matthew Zinn will join Matterport's executive leadership team as the company's chief legal officer, responsible for overseeing the company's global legal, regulatory, privacy, and compliance efforts, as well as serving as the corporate secretary. Mike Knapp joins as the VP and head of investor relations, responsible for Matterport's investor relations strategy with a focus on proactively communicating the company's vision and growth strategy while continuing to build relationships with the investment community. Zinn most recently served as chief legal officer at 8x8 (EGHT).

16:20 EST MAA raises quarterly dividend 12% to $1.40 per share - Payable on January 31, 2023, to shareholders of record on January 13, 2023.

16:18 EST Southside Bancshares increases share repurchase plan by 1M shares - Southside Bancshares announced that its board of directors has increased its authorization under the company's current stock repurchase plan by an additional 1M shares, for a total authorization to repurchase up to 2M shares of the company's common stock from time to time. Under the plan, previously announced March 1, the company has purchased 765,214 shares at an average price of $37.01 through December 12, resulting in approximately 1.2M authorized shares remaining.

16:14 EST Shoals Technologies appoints Ben Macias to CRO, Jessica Uecker to CHRO - Shoals Technologies announced the appointments of Jeff Tolnar, Ben Macias and Jessica Uecker to president, chief revenue officer, or CRO, and chief human resources officer, or CHRO, respectively, effective December 19. As senior VP, EV solutions since April, Tolnar has been responsible for expanding Shoals' solar EBOS solutions into the global EV market to enable more economical, efficient and higher quality EV charging infrastructure deployments. As senior VP of sales and marketing for Shoals since January 2021, Macias has been responsible for sales, marketing, and developing go-to-market strategies for international markets. As senior VP, human resources since June 2021, Uecker has overseen Shoals' human resources function leveraging her more than 20 years of extensive HR experience.

16:11 EST Quanta Services raises quarterly dividend 14% to 8c per share - The dividend is payable on January 13, 2023, to stockholders of record as of January 3, 2023.

16:09 EST Arena Group to buy digital assets of Men's Journal, Adventure Network for $28.5M - The Arena Group Holdings "announced that it has entered into a definitive agreement to acquire the digital assets of Men's Journal, Men's Fitness, Surfer, Powder, Bike, SKATEboarding, Snowboarder and NewSchoolers from accelerate360. The collection of active lifestyle brands, which will provide the core components of The Arena Group's fourth major vertical, has been a staple of those enjoying active and adventurous lives. Under the terms of the acquisition agreement, The Arena Group will pay an aggregate of $28.5 million, including $25 million in cash up front and approximately $3.5 million in deferred payments to acquire these digital assets and assume certain liabilities. The acquisition is expected to be completed Thursday, December 15. "

16:08 EST Global Business Travel Group chief revenue officer to step down - American Express Global Business Travel, which is operated by Global Business Travel Group, "announced its Chief Revenue Officer Michael Qualantone is to retire after a 34-year career with American Express and Amex GBT. Qualantone will begin transitioning his role on January 1, 2023, to Rajiv Ahluwalia, who becomes Executive Vice President. Ahluwalia has led distribution, content, and revenue management at Amex GBT while playing a critical role in driving the Amex GBT marketplace and NDC capabilities. He will report to Chief Commercial Officer Andrew Crawley. To ensure a smooth transition, Qualantone will remain available to the company as an employee until June 30, 2023."

16:07 EST LivaNova announces receipt of close-out warning letter from FDDA - LivaNova "announced it received a close-out letter from the U.S. Food and Drug Administration for the Warning Letter the Company received on December 29, 2015 that was associated with its Munich, Germany facility and 3T Heater-Cooler(TM) device. Closure of the 2015 Warning Letter represents the culmination of LivaNova's corrective actions implemented at its Munich manufacturing facility and to the 3T Heater-Cooler device design."

16:06 EST Toro Company raises quarterly dividend by 13% to 34c per share - This dividend is payable on January 11, 2023, to shareholders of record at the close of business on December 28, 2022.

16:03 EST Amgen announces presentation of results from E1910 randomized Phase 3 trial - Amgen announced the ECOG-ACRIN Cancer Research Group will present results from the E1910 randomized Phase 3 trial. This is the first study to demonstrate superior overall survival, or OS, with BLINCYTO added to consolidation chemotherapy over current standard of care in newly diagnosed adult patients with Philadelphia chromosome-negative B-ALL who were measurable residual disease, or MRD,-negative following induction and intensification chemotherapy. These results were featured in a press briefing on Monday, Dec. 12 as a late breaking oral presentation, or LBA1, at the 64th American Society of Hematology, or ASH, Annual Meeting & Exposition in New Orleans. The Phase 3 randomized trial, or E1910, activated in December 2013, evaluated the safety and efficacy of BLINCYTO added to standard of care consolidation chemotherapy compared to chemotherapy alone in patients with newly diagnosed B-ALL with no MRD after induction and intensification chemotherapy. The primary endpoint was OS and key secondary endpoints included relapse-free survival, MRD status, and incidence of adverse events. Based on a recommendation by the ECOG-ACRIN Data Safety Monitoring Committee and consistent with the pre-defined efficacy threshold, results from the planned interim analysis are now reported due to overwhelming efficacy reported in the BLINCYTO arm. With a median follow up of 43 months, the study met its primary endpoint with a significant improvement in overall survival favoring the BLINCYTO arm; median OS was not reached vs. 71.4 months in the control arm. After about 3.5 years of follow-up, 83% of the patients who went on to receive additional standard consolidation chemotherapy plus experimental BLINCYTO were alive versus 65% of those who received chemotherapy only. No new safety signals were reported for the combination.

16:02 EST Vallon Pharmaceuticals Inc trading halted, news pending

15:46 EST Grupo Televisa trading resumes

14:59 EST Citrix releases security updates to address 'critical vulnerability,' CISA says - Citrix has released security updates to address a critical vulnerability, "CVE-2022-27518," in Citrix ADC and Citrix Gateway, the Cybersecurity & Infrastructure Security Agency announced. " An attacker could exploit this vulnerability to take control of an affected system. This vulnerability has been exploited in the wild. CISA encourages users and administrators to review Citrix security bulletin CTX457836 and Citrix's blog post for more information and to apply the necessary updates. Additionally, CISA urges organizations to review NSA's advisory APT5: Citrix ADC Threat Hunting Guidance for detection and mitigation guidance against tools employed by a malicious actor targeting vulnerable Citrix ADC systems," CISA stated in a notice posted to its website. Reference Link

14:52 EST Televisa confirms talks held with Megacable about potential combination - Grupo Televisa announced that it is aware of press reports regarding a potential merger of its cable business "Televisa Cable" with Megacable Holdings. In a regulatory notice, Televisa stated: "The company today confirmed that it has held bilateral discussions with Megacable from time to time time with respect to a combination, and that on November 14, 2022, it submitted a proposal not binding of the transaction to the Board of Directors of Megacable. Televisa's proposal contemplates a merger of Televisa Cable into Megacable through a share exchange at a premium of approximately 19% for Megacable shareholders, in which the shareholders of Megacable and Televisa would own approximately 45% and 55% of the combined company, respectively. The proposal also includes the possibility that, at the close of the transaction, Megacable shareholders receive a special cash dividend of approximately MXN$14.8 billion. Megacable would continue to be listed on the Mexican stock market as the entity resulting from the merger. The Company believes that the proposed transaction may represent benefits significant for both companies and their shareholders. The combination would create a leading cable operator in Mexico, better positioned to compete in a highly competitive market." Reference Link

14:40 EST Match Group up 8% after Bloomberg report on Apple App store plans - Shares of Match Group (MTCH) are up 8% to $47.17 and those of Bumble (BMBL) are up more than 2% to $24.07 after Bloomberg's Mark Gurman reported that Apple (AAPL) is getting ready to allow alternative app stores on its iPhones and iPads as part of an overhaul to comply with strict European Union requirements that are coming in 2024.

13:40 EST Instagram rolls out Notes for short messaging - Instagram (META) blogged earlier, in part: "Whether it's catching up with friends or exploring shared interests, connecting with others is why people come to Instagram.. we're introducing several updates to help you feel closer to the people you care about. We're beginning to roll out Notes, a new way to share your thoughts and see what your friends are up to. Notes are short posts of up to 60 characters using just text and emojis. To leave a note, go to the top of your inbox, select the followers you follow back or people on your Close Friends list, and your note will appear at the top of their inbox for 24 hours. Replies to notes will arrive as DMs in your inbox...People enjoy sharing throughout their day to Stories - from highlights to the more everyday moments. We're testing new features in Stories to help people more easily share in spontaneous, fun ways to help create even stronger connections with friends. Other companies in the space include Snap (SNAP). Reference Link

13:23 EST Cleveland-Cliffs announces price increase for steel products - Cleveland-Cliffs announced that it is increasing current spot market base prices for all carbon hot rolled, cold rolled and coated steel products by a minimum of $50 per net ton, effective immediately with all new orders. Cliffs' minimum base price for hot rolled steel is now $750 per net ton. This additional price increase is in response to market feedback following the Company's November price increase, as well as improving dynamics in the raw materials and distribution markets.

12:00 EST Direxion Daily Semiconductor Bear 3X Shares falls -7.9% - Direxion Daily Semiconductor Bear 3X Shares is down -7.9%, or -$2.46 to $28.86.

12:00 EST Shares MSCI Taiwan Index Fund falls -15.1% - Shares MSCI Taiwan Index Fund is down -15.1%, or -$7.50 to $42.21.

12:00 EST Pinterest rises 11.5% - Pinterest is up 11.5%, or $2.73 to $26.34.

11:52 EST CohBar treatment of idiopathic pulmonary fibrosis granted orphan status - CohBar's treatment of idiopathic pulmonary fibrosis, or IPF, was granted orphan status by the FDA, according to a post to the agency's website. Reference Link

11:21 EST Pacira sinks after continuing to not provide outlook with monthly sales - Pacira BioSciences, when reporting November net product sales of $57.5M earlier today, said it is still not providing 2022 revenue or gross margin guidance "at this time given the continued uncertainty around labor shortages, COVID-19, and the pace of recovery for the elective surgery market." It added, "To provide greater transparency, the company is reporting monthly intra-quarter unaudited net product sales for Exparel, Zilretta and iovera until it has gained enough visibility around the impacts of COVID-19." Pacira explained that since early 2020, its revenues have been impacted by COVID-19 and pandemic-related challenges "that included the significant postponement or suspension in the scheduling of elective surgical procedures due to public health guidance and government directives." While the degree of impact has diminished during the course of the pandemic, "certain pandemic-related operational challenges persist," the company said. "It remains unclear how long it will take the elective surgery market to normalize or if restrictions on elective procedures will recur due to future COVID-19 variants or otherwise," it added. Shares of Pacira are down 7% to $42.11 in late morning trading.

10:51 EST E*TRADE from Morgan Stanley eliminates commissions for all online mutual funds - E*TRADE from Morgan Stanley has announced it will eliminate all trade commissions and early redemption fees for mutual fund online trades on its platform. "The ability to add mutual funds to the list of E*TRADE's no commission offerings is another proof point that joining Morgan Stanley has provided substantial benefits to clients as we aim to offer the best investing experience possible," said Chad Turner, Head of Morgan Stanley Wealth Management's Digital Direct Channel. "E*TRADE has a long history of being an innovator in the industry and we are proud to be able to advance this narrative even further as part of Morgan Stanley." E*TRADE from Morgan Stanley offers over 6,500 commission-free mutual funds. Clients can use the Fund Screener to find funds that match their goals and investment strategies. The commission-free Mutual Fund offering will be effective for all online mutual fund trades executed on or after December 12, 2022.

10:30 EST Vanda weakness attributed to court opinion in Hetlioz patent case - Vanda Pharmaceuticals shares are up down 7% to $10.05 in morning trading, which Bloomberg attributes as being related to a court opinion being issued in a Hetlioz patent case.

10:17 EST Nuvalent announces publication detailing design of NVL-520 - Nuvalent announced the publication of a manuscript in Cancer Discovery, a journal of the American Association for Cancer Research, which describes the design and characterization of NVL-520 and details Nuvalent's approach to rationally targeting ROS1. NVL-520 is currently being studied in the ongoing ARROS-1 Phase 1/2 clinical trial for patients with advanced ROS1-positive non-small cell lung cancer and other solid tumors. The paper details the design principles underlying the activity of NVL-520 against ROS1 and its most commonly occurring resistance mutation, ROS1 G2032R, and a molecular rationale for the selectivity of NVL-520 for ROS1 over the structurally-related TRK family. TRK inhibition in the CNS by approved or investigational ROS1 TKIs has been associated with neurological adverse events that can be dose limiting. Extensive preclinical characterization of the activity and selectivity of NVL-520 is presented, spanning biochemical and cellular assays, in vivo xenograft studies, and preclinical assessments of brain penetrance and intracranial activity. In addition, the paper includes three case studies of patients with ROS1 fusion-positive lung cancers that had relapsed on or were refractory to a range of ROS1 TKIs, and includes patients with tumors that harbored ROS1 G2032R or had intracranial metastases. NVL-520 elicited tumor responses in the patients with no observed neurological toxicities. These findings support the potential for NVL-520 to treat these patient populations while also enhancing tolerability through improved selectivity for ROS1.

10:06 EST Option Care Health expands partnership with WellSky - WellSky is significantly expanding its partnership with Option Care Health. Option Care Health will collaborate with WellSky to accelerate innovations and workflow enhancements within WellSky's infusion and specialty pharmacy platform, CareTend, and will implement the software across its more than 160 Option Care Health locations.

10:05 EST Haven Foods selects ReposiTrak's traceability solution - ReposiTrakhas welcomed Haven Foods, LLC, to its ReposiTrak Traceability Network, the solution backed by the industry for being easy to adopt and the lowest cost possible. Joining the Network enables Haven Foods to seamlessly exchange traceability information from feed to store between its fresh and frozen seafood suppliers and producers and its retail and restaurant clients across the world, helping it meet and exceed the Food and Drug Administration's recently finalized Food Safety Modernization Act Section 204 rule on traceability.

10:03 EST Novartis reports Phase 3 APPLY-PNH trial met both primary endpoints - Novartis announced detailed results from the pivotal Phase 3 APPLY-PNH trial. The results showed a vast majority of patients with paroxysmal nocturnal hemoglobinuria, or PNH, who received the investigational oral monotherapy iptacopan achieved clinically meaningful increases in hemoglobin levels compared to anti-C5 therapy. The study met both primary endpoints and most secondary endpoints, with iptacopan demonstrating superiority over anti-C5 therapy in adult patients with PNH experiencing residual anemia despite prior treatment with anti-C5 therapy. The study met both primary endpoints, showing superiority for iptacopan vs. anti-C51. For the first, an estimated 82.3% of iptacopan-treated patients achieved hemoglobin-level increases of 2 g/dL or more from baseline without the need for red blood cell transfusions, compared to an estimated 2.0% of anti-C5-treated patients: an estimated 80.3% difference in favor of iptacopan. The observed number of patients achieving this primary endpoint was 51/60# for iptacopan vs. 0/35 for anti-C5. For the second primary endpoint, an estimated 68.8% of iptacopan-treated patients achieved hemoglobin levels of 12 g/dL or more without the need for blood transfusions, compared to an estimated 1.8% of anti-C5-treated patients: an estimated 67.0% difference in favor of iptacopan. The observed number of patients achieving this primary endpoint was 42/60# for iptacopan vs. 0/35 for anti-C5.

10:01 EST L3Harris awarded potential $886M contract supporting battlespace ISR - The U.S. Army Communications-Electronics Command awarded L3Harris Technologies a contract worth up to $886M to support intelligence, surveillance and reconnaissance capabilities for the Army, Department of Defense and intelligence community. The indefinite delivery, indefinite quantity contract includes a five-year base award with five one-year follow-on options to provide datalink architecture, network design enhancements for aerial and ground-based communications, and lifecycle management support.

10:00 EST Small Cap Bear 3x falls -9.8% - Small Cap Bear 3x is down -9.8%, or -$3.17 to $29.05.

10:00 EST Shares MSCI Taiwan Index Fund falls -14.4% - Shares MSCI Taiwan Index Fund is down -14.4%, or -$7.17 to $42.54.

10:00 EST Direxion Daily Semiconductor Bull 3X Shares rises 14.2% - Direxion Daily Semiconductor Bull 3X Shares is up 14.2%, or $1.84 to $14.82.

09:47 EST Debt Resolve falls -9.3% - Debt Resolve is down -9.3%, or -$4.62 to $44.95.

09:47 EST Shares MSCI Taiwan Index Fund falls -14.5% - Shares MSCI Taiwan Index Fund is down -14.5%, or -$7.21 to $42.50.

09:47 EST Direxion Daily Semiconductor Bull 3X Shares rises 12.1% - Direxion Daily Semiconductor Bull 3X Shares is up 12.1%, or $1.57 to $14.55.

09:46 EST Knightscope announces contracts for ASRs, Blue Light Towers, Call Boxes - Knightscope announces the largest single contract in the Company's history alongside 2 new contracts from cities in New York and Georgia. The contracts consist of 12 K5 Autonomous Security Robots, 2 K1 Blue Light Towers and 2 K1 Call Boxes. A key decision-making factor for the larger client was the K5's capabilities that are not part of the current security program. The company will be deploying ASRs as part of an overall "layered" approach to give them unprecedented eye-level views and coverage. The ASRs will deter crime, criminal trespassing and loitering while providing their employees with greater personal safety. The two cities electing to expand their communication capabilities selected Knightscope K1 Blue Light Emergency Towers and Emergency Call Boxes using cellular and satellite communications with solar power to provide additional safety in remote locations. These newer, more advanced wireless systems will save end users money on both infrastructure and hardware costs, while improving reliability on a modern communication network.

09:32 EST Backblaze announces new data region in the Eastern U.S. - Backblaze expanded with a new data region in the Eastern United States. The U.S. East data region provides more location choice overall, bringing increased access speed for customers based in the Eastern U.S. and greater geographic separation for backup data stored by businesses operating in other regions. The new region also helps provide an additional destination for businesses seeking to store copies of their datasets to two or more cloud locations for compliance and continuity needs. This Cloud Replication service is provided with free data egress, enabling customers to copy data across the Backblaze platform at no expense. Data stored in U.S. East will reside in Backblaze's newest data center, IAD 1, located in Reston, Virginia. This data center features an exabyte of capacity with room to grow further, and supports SOC 2 Type 2, ISO 27001, NIST 800-53, and HIPAA compliance requirements to help ensure that data in the East region is safe and readily available for Backblaze customers.

09:30 EST Opal Fuels Inc trading halted, volatility trading pause

09:26 EST SeqLL appoints Brian Paras as CBO - SeqLL announced that Brian Paras has joined the company as Chief Business Officer. Prior to joining SeqLL, Mr. Paras held senior commercial leadership positions with life-science technology providers including Affymetrix, Covaris, Helicos Biosciences, Nabsys, and Caliper Life Sciences.

09:25 EST NYSE American to suspend trading immediately in Winc - NYSE American announced that the staff of NYSE Regulation has now determined to immediately suspend trading in the common shares of Winc, Inc. - ticker symbol WBEV - from the Exchange. On December 5, the NYSE American announced that it was commencing proceedings to delist the company. The company had the right to request a review of this determination by a Committee of the Board of Directors of the Exchange. On December 12, the company confirmed that it will not exercise that right. Accordingly, the NYSE American will now suspend trading in the common shares and will file a delisting application with the Securities and Exchange Commission. Reference Link

09:20 EST Aesther Healthcare Acquisition to extend period to consummate combination - As previously announced, on August 31, 2022, Aesther Healthcare Acquisition Corp. entered into definitive merger agreement with Ocean Biomedical, Inc. Aesther announced today that its Board of Directors has approved an extension of the period of time available to Aesther to consummate a business combination by three months from December 16, 2022 to March 16, 2022, as permitted under Aesther's governing documents. In connection with the Second Extension, Aesther's sponsor, Aesther Healthcare Sponsor, LLC, has agreed to deposit an aggregate of $1,050,000 into Aesther's Trust account for its public stockholders, representing $0.10 per public share, by December 16, 2022, which will be in the form of a loan. Aesther's governing documents permit a total of two three-month extensions, of which this is the second.

09:18 EST Alkaline Water adds two new direct-store-delivery partners - The Alkaline Water Company announced that it has added two new direct-store-delivery partners, C&M Sales and Alber & Leff Foods Company to cover the entire state of Arkansas and Western Pennsylvania, respectively. Alkaline88 now has DSD coverage in fourteen states as it continues to grow sales in the convenience and grocery channels. "The addition of two great new DSD partners will help Alkaline88 continue to grow in important regional grocery chains as well as earn shelf space in more of the 150,000 convenience stores in the country," said Frank Lazaran, President and CEO of The Alkaline Water Company.

09:18 EST Brainsway reports open market stock purchase by board member - BrainsWay reported a recent open market purchase of BrainsWay American Depositary Receipts by Yossi Ben Shalom, an independent Director on the Company's Board. Ben Shalom purchased 147,500 ADRs on the open market for a total amount of $277,300, at an average price of $1.88 per ADR. The ADR purchase was made on the Nasdaq exchange, and follows recent open market stock purchases by additional BrainsWay board members, including its Chairman, Dr. David Zacut, and Avner Hagai. The Company's ordinary shares are listed and traded on the Tel Aviv Stock Exchange.

09:15 EST Winc Inc trading halted, news dissemination

09:10 EST A2Z announces 30% increased advanced smart cart order from Yochananof - A2Z Smart Technologies announces that it has received an increased purchased order of 30% from a leading grocery chain M. YOCHANANOF AND SONS. This now brings the total order to 1,300 smart carts and total aggregate revenues to approximately New Israeli Shekels 35M or or $12M. Pricing and delivery terms are in line with the original agreement and payment will be made in advance for each batch of smart carts delivered. To date, Yochananof has paid the Company approximately NIS 20M, USD $5.8m. Delivery of the initial purchase order continues at pace with 11 Yochananof stores now utilizing the Cust2MatSmart Cart solution. The Company anticipates completion of the initial purchase order and the increased purchased order by the end of Q223.

09:09 EST Euronet announces Ren Payments Platform selected by BNC - Euronet Worldwide announced its Ren Payments Platform will serve as the foundational technology for the digital payments transformation strategy at Bank Neo Commerce, BNC, one of the leading digital banks in Indonesia. BNC selected Euronet and Ren to help make its digital payments faster, accessible and safer for its customers. Retail digital payment transactions in Indonesia have grown 500% from $14B to $72B in the past 5 years with projections for further growth by 60-80% over the next 4-5 years, making Indonesia one of the top countries in the world in regard to rapidly growing digital payments usage. Adoption of BNC's products and services are also growing with quick adoption in terms of downloads, daily active users and monthly active users in Indonesia. As of June 2022, BNC had 18.4 million total customers with monthly active users reaching 3 million. The company hopes to add 15 million new customers by the end of 2022.

09:08 EST Immersion renews multi-year license with Dongwoon Anatech - Immersion announced that it renewed a multi-year license with Dongwoon Anatech, which creates analog integrated circuits, or ICs, for phones, wearables, and other electronic devices, to make Immersion haptic patent licenses available to mobile phone, wearable, and PC OEMs through Dongwoon.

09:06 EST Confluent appoints Shaun Clowes as chief product officer - Confluent announced the appointment of Shaun Clowes as chief product officer, or CPO. As chief product officer, Clowes will lead the strategy and execution of all product-related activities within Confluent, including product innovation and the product roadmap. Clowes joins Confluent from Mulesoft, where he served as CPO, and before that, Atlassian where he served as the head of growth.

09:05 EST C3.ai gets 1st three orders in five year $500M pact with U.S. MDA - C3 AI has received the first three orders in its five-year, $500M Production-Other Transaction Agreement sponsored by the U.S. Missile Defense Agency or MDA, which will be applicable across the Department of Defense . All three orders will leverage the C3 AI Platform to accelerate deployment of critical enterprise artificial intelligence capabilities across the MDA. "An enterprise AI platform that allows for credible assessment of combined kinetic and non-kinetic effects across domains is critical to optimize and correctly evaluate missile defense mission effectiveness," said Ed Abbo, C3 AI President and CTO. "We are thrilled to fulfill the MDA's first three orders in our five-year partnership." "The insights extracted from large volumes of sensor, network, and weapon system test data are critical to analyzing the operational effectiveness, suitability, and survivability of the Missile Defense System," said Dr. Shari Feth, MDA Innovation Science and Technology Director. "The deployment of an enterprise AI platform has allowed MDA to demonstrate robust end-to-end capabilities for collaborating on AI model development and rapidly deploying insights into new production applications."

09:04 EST C3.ai receives first three orders in five-year, $500M MDA agreement - C3 AI has received the first three orders in its five-year, $500M Production-Other Transaction Agreement sponsored by the U.S. Missile Defense Agency, or MDA, which will be applicable across the Department of Defense, or DoD. All three orders will leverage the C3 AI Platform to accelerate deployment of critical enterprise artificial intelligence capabilities across the MDA.

09:02 EST Digerati Technologies' NextLevel Internet launches CCaaS solution - Digerati Technologies announced the roll-out of a new Contact Center as a Service solution. This new Omni-Channel CCaaS offering, which will initially be available through Digerati's subsidiary NextLevel Internet, will enhance the portfolio of solutions the Company is currently offering to the SMB marketplace. NextLevel's new intelligent Contact Center suite of services uses a combination of artificial intelligence, workflow automation, virtual agents, intelligent call routing, integrations, reporting, and employee collaboration tools to help businesses reduce costs and improve the customer experience, all without the need to add additional resources. As a cloud-based solution, NextLevel's Contact Center allows its business users to deliver superior customer care from anywhere.

09:02 EST Panasonic Energy, Lucid Group announce battery supply agreement - Panasonic Energy Co., a Panasonic Group (PCRFY) company, and Lucid Group (LCID) announced they have entered into multi-year agreements to supply batteries for Lucid's award-winning luxury electric vehicle, Lucid Air, the fastest-charging, longest range EV on the market, and Lucid's upcoming Gravity SUV. The agreement marks another milestone in Panasonic's plans to expand production of lithium-ion EV batteries beyond Japan and into the U.S. with production coming from both a facility in Japan, as well as expected future production from its recently announced battery production facility in De Soto, Kansas.

08:57 EST Itron signs contract with GRU to modernize infrastructure - Itron announced that they signed a contract with Gainesville Regional Utilities, or GRU, a multi-service utility owned by the City of Gainesville, to modernize the utility's infrastructure with Itron's multi-purpose industrial IoT, or IIoT, network solution, including smart Gen 5 500W water and Gen 5 500G gas communication modules and Gen5 Riva Distributed Intelligence enabled electric smart meters. The utility will also take advantage of Itron Enterprise Edition Meter Data Management as a Software-as-a-Service to manage meter and sensor data. These solutions will allow GRU to improve operational efficiency, data collection accuracy and enhance customer service. The utility plans to deploy Itron's solutions across Gainesville and surrounding areas.

08:55 EST Patria Investments announces divestment of ODATA, Entrevias - Patria Investments announced definitive agreements for the divestments of ODATA, a Brazilian data center service provider, and Entrevias, a toll road operator in the state of Sao Paulo. Together these transactions are expected to generate approximately $1.4 billion in proceeds for investors in Patria's Infrastructure Fund III. ODATA is a data center service provider offering scalable, reliable and flexible IT infrastructure. It is among the fastest growing hyperscale data center platforms in the Latin America, with operational facilities strategically located across Brazil, Colombia, Mexico and Chile, as well as additional data centers currently under development across the region. Aligned Data Centers, a leading technology infrastructure company offering innovative, sustainable and adaptive Scale Data Centers and Build-to-Scale solutions for global hyperscale and enterprise customers, has entered into a definitive agreement to acquire ODATA from Patria Infrastructure Fund III and other selling stakeholders, marking its expansion into Latin America. On December 1, 2022, Patria also announced the divestment of 55% of its stake in Entrevias Concessionaria de Rodovias to VINCI, a world leader in concessions, energy and construction. Entrevias was created by Patria in 2017, and operates a 30-year concession encompassing 570 kilometers of toll roads that cross the state of Sao Paulo. The concession entailed significant capex investment by Patria to restore, enlarge and implement new technologies throughout the existing highway to improve the transportation matrix for both passengers and cargo, and foster the connection and development of surrounding regional economic centers. Patria's Infrastructure Fund III will continue to own the remaining 45% of Entrevias. The divestment of ODATA and Entrevias will bring cumulative distributions to fund investors to approximately $2 billion, surpassing a full return of capital, and bringing the fund near to the performance hurdle threshold, beyond which it enters the "100% catch up" phase and can begin realizing the accrued performance fees.

08:52 EST Bruush electric toothbrush to be featured item on home shopping channel TSC - Bruush Oral Care will be participating in a one-day sales campaign on the home shopping channel, Today's Shopping Choice, on Friday December 16, 2022. This will be the Company's second appearance on the home shopping channel, with their first appearance having taken place in September. TSC is Canada's only nationally televised shop-from-home service, reaching into over 7 million households across the country and is actively watched by almost 1.5 million viewers weekly. Through the campaign with TSC, Bruush hopes to reach a broader audience this holiday season and will showcase its most popular colors while on the air. Earlier this month, the Company launched two seasonal colors - Arctic Blue and Midnight Blue - which will be available on a limited-edition basis through the holiday period.

08:50 EST American Acquisition target Royalty Management becomes CASFER member - American Acquisition Opportunity merger target company, Royalty Management Corporation announced that it has become a gold member of Texas Tech University's recently created Center for Advancing Sustainable and Distributed Fertilizer Production, or 'CASFER' organization. Becoming a gold members of CASFER enables RMC to have access to the technologies and intellectual property developed out of CASFER, in particular the innovative and novel technologies to produce, capture, and recycle nitrogen-based fertilizers resulting from farming activities.

08:47 EST Nocera reports $3.2M in eel sales revenue in November - Nocera announced that it has hit a record-breaking revenue for the month of November, reaching approximately $3.2M in eel sales revenue.

08:44 EST Predictive Oncology announces appointment of Malandro to SAB - Predictive Oncology announced the appointment of Marc Malandro, Ph.D., to the company's Scientific Advisory Board, SAB, where he will serve alongside other key thought leaders in their respective fields to guide the company's scientific initiatives and growth strategy. Dr. Malandro currently serves as the Vice President of Operations for Science at the Chan Zuckerberg Initiative, where he is part of the team that partners, supports and builds novel advances and tools to enable and accelerate biomedical research.

08:43 EST KULR's CellCheck Battery Monitoring System launches on Microsoft's Azure - KULR Technology Group (KULR) announced that its CellCheck Battery Monitoring System is now running on the Azure Cloud Computing Service by Microsoft ( MSFT). This next-generation battery safety technology captures real-time and lifetime battery data allowing it to detect adverse electrical, environmental and physical events resulting in maximum battery safety, reliability, and performance. In its new iteration, CellCheck devices can wirelessly transmit live sensor data from the edge to the Azure Cloud where it is displayed on an extensive dashboard system. "Electrifying the circular economy will generate vast streams of high-value data," said Keith Cochran, President and COO of KULR Technology Group. "We are developing cutting-edge solutions that enable our customers to realize the full value of this data - from using predictive analytics for preventing thermal runaway, to using battery intelligence data for enhancement of operational performance, to using sustainability data to visualize ESG and climate impact. CellCheck technology will dramatically increase the safety of battery packs by providing instant analysis of current and historic health. We believe this to be a game-changing product for the $44 billion lithium-ion battery market."

08:42 EST ContraFect announces pricing of $7M registered directoffering - ContraFect Corporation entered into a securities purchase agreement with a single institutional investor to purchase approximately $7.0 million of its common stock in a registered direct offering and warrants to purchase common stock in a concurrent private placement. The combined effective purchase price for each share of common stock and associated warrants will be $0.129. nder the terms of the securities purchase agreement, ContraFect has agreed to issue 4,350,000 shares of common stock and pre-funded warrants to purchase 49,913,565 shares of common stock. In the concurrent private placement, which will be consummated concurrently with the offering, ContraFect also has agreed to issue Class A warrants to purchase up to an aggregate of 108,527,130 shares of common stock and Class B warrants to purchase up to an aggregate of 54,263,565 shares of common stock. Each of the warrants is subject to a customary beneficial ownership limitation on exercisability, and the Class A warrants and Class B warrants will not be exercisable at all until ContraFect obtains a shareholder approval of an amendment to the Company's certificate of incorporation for either an increase in authorized shares of its common stock or a reverse split of its common stock and a shareholder approval as required under the Nasdaq rules with respect to this transaction. Each of the Class A warrants and Class B warrants will have an exercise price of $0.129 per share of common stock. The Class A Warrants will expire five years from the date on which they become exercisable. The Class B warrants will expire six months from the date on which they become exercisable. Maxim Group LLC is acting as the sole placement agent for the offering. The offering is expected to close on or about December 15, 2022, subject to the satisfaction of customary closing conditions.

08:41 EST RYVYL Inc. says 'no exposure to crypto firms' that filed for bankruptcy - RYVYL announced a letter to shareholders regarding recent events in the cryptocurrency market and the implications on RYVYL, which read in part, "It's been a tumultuous end to 2022 for the cryptocurrency marketplace with the fall of FTX and BlockFi among other firms, along with the sharp decline in the price of cryptocurrencies and related securities. In the wake of this crises, we at RYVYL now more than ever want to clearly communicate the conviction that we have in our differentiated suite of payment technology solutions that arm us to seize on a fantastic opportunity and emerge as a leader in the digital payments space. RYVYL is not a cryptocurrency firm and has no exposure to crypto firms that have recently filed for bankruptcy protection. The collapse of crypto exchanges only strengthens our position and validates the strategy we have taken. Our smart contract token, known as coyni, has a unique architecture as a USD-pegged stablecoin, backed dollar for dollar in a federally insured custodial account with near real-time attestation, ensuring the continuous health and compliance of the ecosystem. Our technology settles through a proprietary blockchain ledger that we believe is the ideal digital payments product on the market today. To clarify, each coyni digital token is held in a wallet on the platform and matched with one U.S. dollar held in a custodial account by a federally insured financial institution. The dollars backing coyni are not tied up in investments or US treasury notes and are not converted to cryptocurrencies. All industry failures we have seen recently, in both stablecoin and crypto, occurred with ecosystems that did not utilize these safety measures, leading to severe market disruption. We continue to support regulatory oversight along these principles. One of the most significant points of distinction for us is that coyni has near real-time custodial account attestation. This was no small feat and accomplished only after a lengthy review of IT, compliance and, specifically, SOC 2 compliance certification from Armanino, a top accounting, consulting and technology firm in the U.S. The recent crypto market collapse will undoubtedly lead to increased regulatory oversight, something which we welcome and believe will be beneficial to our business and growth trajectory. As oversight increases and stablecoin matures, we believe there will be less need for volatile cryptocurrencies. We believe a stablecoin that is properly pegged to fiat currency, both in coverage and compliance reporting, is equivalent to fiat and is likely to eventually be even better than fiat as it has the potential of being adjusted or hedged by commodity. This is where RYVYL can step in. While some large banks work with the Federal Reserve on a recently announced pilot-program leveraging blockchain backed stablecoin technology, we are already in the market as demonstrated by our successful work in American Samoa. With a closed-loop payment system already in operation, we bring to market our leading-edge digital payment solutions across the banking sector and in multiple countries to quickly achieve scale and market share. While market conditions have made for a challenging year for stocks in our sector and presented obstacles to our acquisition strategy, we believe the latest fallout in the crypto landscape provides all the opportunity we need to become a disruptive force in the digital payments market and deliver sustainable long-term growth for our shareholders."

08:39 EST Sellas Life Sciences announces Phase 1 data with GFH009 - SELLAS Life Sciences Group announced positive results from its ongoing dose escalating Phase 1 first-in-human study of its highly selective CDK9 inhibitor, GFH009, in patients with relapsed and/or refractory hematologic malignancies. Results include preliminary safety and efficacy data presented this week at the American Society of Hematology, ASH, Annual Meeting, along with updated data since the ASH abstract cutoff date of August 2, 2022. One patient treated with GFH009, in the 30 mg once per week cohort, achieved a confirmed complete response, which is the first CR reported in acute myeloid leukemia with any CDK9 inhibitor monotherapy. No minimal residual disease was detected in this CR patient and full neutrophil, platelet and red blood cell recovery was reported. Anti-cancer effects were also observed at multiple dose levels in both the r/r AML and r/r lymphoma treatment groups. Neutrophil counts improved in most patients from both groups while on treatment, and drug-related severe neutropenias were observed in less than 10% of enrolled patients. Dose limiting toxicities have not been identified at any of the levels studied to date and the maximum tolerated dose has not yet been reached. A total of 57 patients have been enrolled to date, including 31 with r/r lymphoma and 26 with r/r AML. All enrolled patients to date were heavily pretreated with up to six lines of previous therapy. New dosing regimens added to the ongoing trial include 40 mg administered twice per week and 30 mg, 45 mg and 60 mg administered once a week, all of which have been fully enrolled except for the 60 mg cohort. All initially planned dose escalation cohorts with 2.5 mg, 4.5 mg, 9 mg, 15 mg, 22.5 mg and 30 mg of GFH009 administered twice per week are also fully enrolled. The 45 mg once a week cohort, although fully enrolled, has not yet been analyzed. Selective Preliminary GFH009 Monotherapy Efficacy Data in r/r AML Group: One patient has a confirmed CR and is MRD negative after failing azacytidine-venetoclax regimen; One patient continued on treatment for 3 months; Two patients had blast count decreases of greater than or equal to50% in bone marrow. Selective Preliminary GFH009 Monotherapy Efficacy Data in r/r Lymphoma Group: 2 patients had partial response; 4 patients achieved SD with one of them maintaining SD for over a year while still continuing GFH009 monotherapy; The pharmacokinetics profile of GFH009 shows dose proportional concentrations with a biphasic profile of rapid initial tissue distribution followed by slower elimination from tissues. There were no apparent time-dependent changes in volume of distribution or clearance.

08:37 EST Biosyent announces renewal of normal course issuer bid - BioSyent announced that the TSX Venture Exchange has accepted the Company's Notice of Intention to Make a Normal Course Issuer Bid. Pursuant to the NCIB, BioSyent may purchase up to 690,000 of its common shares over a 12-month period, representing approximately 5.70% of the Shares outstanding as of December 13, 2022. The NCIB will commence on December 19, 2022 and terminate on December 18, 2023, or such earlier date on which purchases under the NCIB have been completed. Purchases of Shares under the NCIB will be made through the facilities of the TSX-V or alternative Canadian trading systems at the market price of the Shares at the time of acquisition. The number of Shares the Company is permitted to purchase during any 30-day period is limited to 241,957 Shares, representing 2% of the total outstanding Shares. BioSyent has entered into an automatic share purchase plan with a broker, Raymond James Ltd., in connection with the NCIB to allow for the purchase of Shares during certain pre-determined blackout periods. Outside of these pre-determined blackout periods, Shares will be purchased at the discretion of senior management of BioSyent. BioSyent believes that the Shares may from time to time trade in a price range that does not adequately reflect the value of the Shares in relation to its activities and future prospects. As a result, BioSyent believes that the purchase of Shares, from time to time, would be an appropriate use of corporate funds in light of potential benefits to remaining shareholders. BioSyent has repurchased and cancelled a total of 2,200,625 Shares under NCIBs between December 10, 2018 and December 12, 2022.

08:36 EST Adeia renews multi-year IP license agreement with SONIFI - Adeia announced that it has renewed a multi-year agreement with SONIFI Solutions to license Adeia's media intellectual property portfolio. SONIFI has served the hospitality industry for over 30 years, offering technology solutions that enhance the engagement, entertainment and digital experience of hotel and resort guests. "SONIFI is addressing the evolving needs of the hospitality industry as the world emerges from travel restrictions imposed by a global pandemic that had constrained business and leisure travel. We are excited about the relationship Adeia is building with one of the leading technology providers to a sector that is of critical importance to the global economy," said Dr. Mark Kokes, Adeia's chief licensing officer and general manager, media. "Our license agreement with SONIFI further confirms the value and longevity of Adeia's media IP portfolio for organizations serving the traveling public's needs and we are excited to both expand and extend our relationship with them."

08:33 EST Quoin announces dosing of first patient in trial in Netherton Syndrome - Quoin Pharmaceuticals announces that the first patient has been dosed in its ongoing clinical trial evaluating the safety and efficacy of QRX003 as a treatment for Netherton Syndrome. Quoin's first clinical trial is a randomized, double blinded, vehicle-controlled study which is being conducted under a U.S. Investigational New Drug, IND, Application and is assessing two different doses of QRX003 topical lotion versus a vehicle lotion in Netherton patients. The test materials are applied once daily over a twelve-week period, to pre-designated areas of the patient's body. Based on discussions with the U.S. Food and Drug Administration, FDA, a number of different clinical endpoints will be assessed in the study. In October 2022, Quoin announced it plans to initiate a second study assessing its QRX003 topical lotion in Netherton patients who are currently receiving off-label treatment including systemic therapy for symptomatic relief. This second study, which has now been cleared by the FDA to initiate clinical testing, is an open-label, non-placebo controlled trial that will evaluate 10 Netherton patients over a twelve week period. The study, which will run concurrently with Quoin's ongoing clinical trial, will be conducted at the same sites and by the same clinical investigators as the first study, thereby optimizing the potential for a rapid recruitment of patients. Quoin CEO, Dr. Michael Myers, said, "With over seventy potential candidates already having gone through our initial screening process, we have been delighted with the level of interest in our clinical programs that has been shown by the Netherton community. The dosing of our first patient and the clearance of our second study are big steps forward for Quoin and, hopefully, for the community in general. With all six clinical sites on track to be fully opened this month, we are hopeful that the rate of recruitment into both studies will accelerate rapidly going forward.

08:27 EST Humacyte hosts KOL webinar on vascular trauma - Humacyte announced that it will host a key opinion leader webinar on its proprietary Human Acellular Vessels in the treatment of wartime vascular trauma on Thursday, December 15, 2022 at 8:00 AM ET. The event will feature presentations from several Ukrainian surgeons discussing use of the HAV to treat multiple cases of war induced traumatic injuries. The HAV has received priority designation for the treatment of vascular trauma from the U.S. Secretary of Defense. The HAV is highly resistant to infection and is designed to offer off-the-shelf availability for the repair of injured blood vessels. The HAV is made in a bioreactor bag that can be shipped and stored, so that the HAV can be immediately available when needed to repair vascular injuries. The HAV is designed to address long-standing limitations of vascular tissue repair and replacement in acute injuries, both in civilian and combat settings. The HAV results included in these presentations are part of Humacyte's humanitarian relief initiative in Ukraine. In June 2022, Humacyte provided investigational HAVs to multiple front-line Ukrainian hospitals for the treatment of patients with traumatic vascular injuries sustained during the conflict. In the United States, Humacyte is also evaluating the HAV for treatment of civilian vascular trauma in a Phase 2/3 clinical trial. Patients enrolled in the Phase 2/3 trial have no suitable autologous vein for reconstruction of their traumatic injuries, and many have contaminated wounds that make synthetic conduits not amenable for use. The HAV is an investigational product and has not been approved for sale by the FDA, the Ukrainian Ministry of Health, or any international regulatory agency.

08:24 EST Harsco announces Tosyali Harsco signs 10-year contract with Tosyali Holding - Harsco Corporation announced that Tosyali Harsco, Harsco's joint venture with Tosyali Holding, Turkey's leading flat steel and steel pipe producer, signed a 10-year contract with an estimated revenue of $210M USD to provide services at the company's green field steel plant in Sariseki, Iskenderun. Initial plant commissioning is set to begin at the new green field steel plant in Sariseki, in March 2023. The plant is a significant investment of nearly $2.5 billion USD value for Tosyali and will include a total 4 million ton capacity, two Quantum electric arc furnaces, slab and billet casting machines, a hot rolling mill, and long and flat product finishing lines. Tosyali Harsco's scope of work at the new Sariseki plant will include the treatment of all scraps via sorting, shearing, lancing and cleaning processes, scrap handling and logistics to the melt shop, underfurnace cleaning, ladle slag handling and slag processing. "I would like to congratulate our team for the outstanding performance that made this win possible," said Harsco Environmental Chief Operating Officer Russ Mitchell. "This expanded relationship is a testament to Tosyali's confidence in our ability to deliver services that advance both their business and environmental goals."

08:23 EST Salarius Pharmaceuticals presents clinical data on seclidemstat - Salarius Pharmaceuticals announced that investigators in the Department of Leukemia at the University of Texas MD Anderson Cancer Center presented clinical data on seclidemstat in patients with MDS and CMML at the 64th American Society of Hematology, ASH, Annual Meeting and Exposition underway in New Orleans and virtually. Seclidemstat is a novel oral, reversible, targeted LSD1 inhibitor. The objective of this investigator-initiated Phase 1/2 dose-escalation study is to evaluate the safety, tolerability, maximum tolerated dose and overall response of seclidemstat in combination with azacitidine in adult patients with higher-risk MDS or CMML who previously failed or relapsed after hypomethylating agent therapy. As of October 2022, nine patients were enrolled with a median follow-up time of 3.9 months. Typically, overall survival is four to six months for patients after failing therapy with hypomethylating agents. As presented at ASH, no serious adverse events were reported and all adverse events observed in the study were manageable. Of the eight evaluable patients, four had an objective response including one complete response patient who is planned to receive potentially curative allogeneic stem cell transplantation, two marrow complete responses plus hematological improvement and one marrow complete response. The Phase 1 dose-escalation portion of this study will evaluate up to six dose levels of seclidemstat. The maximum tolerated dose, which will inform the Phase 2 portion of the study, was not yet reached. "We are encouraged that this investigator-initiated trial, which is separate from Salarius' sponsored sarcoma trial, shows promising results at this early stage of the study when seclidemstat is combined with azacitidine," said David Arthur, president and chief executive officer of Salarius Pharmaceuticals. "Patients who have failed prior treatments including hypomethylating agents typically have an overall survival of four to six months and are in desperate need of new treatment options. With a 50% overall response rate, including a complete remission planned for potential curative allogeneic stem cell transplantation, we are hopeful that seclidemstat will play a role in their treatment paradigm."

08:21 EST Just Energy CEO Scott Gahn takes leave of absence for health reasons - Just Energy Group announced that Scott Gahn, its CEO, will be taking an immediate leave of absence for health reasons. The Just Energy Board of Directors has appointed Michael Carter, the Company's CFO, as interim President and CEO, effective immediately. As a member of the leadership team since 2020, Mr. Carter is deeply involved in the operations of Just Energy and, with the support of the other members of the executive management team, is well-positioned to lead the Company out of its restructuring phase, upon the close of the previously announced transaction under the Companies' Creditors Arrangement Act.

08:18 EST Guardian Capital to remove lifetime carbon balance by 2040 - Guardian Capital Group announced its commitment to fully remove its lifetime carbon balance - the total greenhouse gas emissions from its operations since the company's inception - by December 31, 2040. Guardian will eliminate its LCB over 19 years, through annual investments in carbon removal projects, in partnership with The Pond Foundation, of which it is a founding member. As part of this initiative, The Pond Foundation team has prepared an assessment and report of Guardian's LCB from the company's inception in 1962 through to December 31, 2021. The evaluation covered over six decades of data and was based on the Greenhouse Gas Protocol, the international standard for corporate accounting and reporting of emissions, which categorizes greenhouse gasses into Scope 1, 2 and 3 emissions, based on the source. Through this analysis, the assessment determined that Guardian's LCB was 35,219 tonnes of C02 equivalent. As a result, in addition to Guardian's existing commitment to balance its annual carbon emissions footprint starting in 2022 by reducing its own emissions and investing in external, nature-based projects that remove carbon from the atmosphere, Guardian has now committed to completely removing these lifetime emissions by the end of year 2040. The amount for the first year will be removed by investing in the following three projects: Ricehouse - Promotes the circular economy from the field to the house with rice-based construction material in Italy. Durrell Rewild Forest Restoration - Contributes to the conservation of 1,000 highly endangered black lion tamarins, restores new forest and creates direct employment for 250 families in their region of Brazil, where poverty incidence is up to 47%. Tanoe-Ehy Forest - Aims to improve livelihoods and governance structures for local people in the Ivory Coast, protect critical habitats and biodiversity, help to reduce illegal logging and bushmeat hunting and more.

08:16 EST Nuwellis announces peer-reviewed publication on Aquadex - Nuwellis announced the peer-reviewed publication of the results from a 10-year, real-world retrospective analysis of 334 hospitalized acute decompensated heart failure patients with fluid overload treated with adjustable ultrafiltration using the Aquadex FlexFlow System. Published in the American Heart Journal Plus, the analysis conducted by investigators at Abington Hospital-Jefferson Health in Abington, Pennsylvania demonstrated significant reductions in heart failure hospitalizations and 30-day hospital readmission rates, as well as improvements in renal function response, using Aquadex ultrafiltration. The published study, titled "Ten-Year Real-World Experience with Ultrafiltration for the Management of Acute Decompensated Heart Failure," findings included: Patients experienced an overall 81% decrease in heart failure hospitalizations per year; Rehospitalizations for patients after receiving UF with Aquadex were 48% less than the national average at 30 days; 55% of patients achieved sustained weight loss greater than 15 lbs.; and All patients had stable renal function at follow-up. "These results are consistent with the AVOID-HF Win Ratio analysis recently presented at the Heart Failure Society of America 2022 Annual Scientific Meeting that demonstrated statistically significant clinical superiority of ultrafiltration therapy using the Aquadex System over diuretics in reducing heart failure events within 30 and 90 days," said Nestor Jaramillo, Jr., President and CEO of Nuwellis. "We are grateful to both Dr. Haas and Dr. Robert Watson, Principal Investigator and Chief of Cardiology and Co-Director, and to the study's Sub-Investigators, Maureen Hummel, CRNP, and Patricia Barrella, RN, MSN, for studying their center's experience with Aquadex FlexFlow. We look forward to helping other healthcare providers learn from their findings. Nuwellis is committed to making Aquadex therapy the standard of care for fluid management in heart failure patients that are unresponsive to diuretics."

08:14 EST Oric Pharmaceuticals presents preclinical data on ORIC-533 - ORIC Pharmaceuticals presented preclinical ORIC-533 data demonstrating a potential best-in-class CD73 inhibitor profile for the treatment of multiple myeloma."ORIC-533 continues to demonstrate strong potency in reducing adenosine generation and thereby overcoming immune suppression and restoring lysis of multiple myeloma cells as a single agent in ex vivo models," said Jacob M. Chacko, MD, chief executive officer. "We look forward to sharing initial clinical data from the ongoing Phase 1b study of ORIC-533 in patients with multiple myeloma in the first half of 2023." Key highlights from the presentation include: Preclinical analyses continue to show ORIC-533 demonstrates a potential best-in-class CD73 inhibitor profile. ORIC-533 overcame immune suppression and triggered significant lysis of multiple myeloma cells across all dose levels tested and in a dose-responsive manner, in an autologous ex vivo assay using samples derived from bone marrow aspirates from patients with relapsed refractory multiple myeloma. Together these preclinical data confirm that single agent ORIC-533 inhibits CD73 to potently reduce adenosine generation, overcome immune suppression and restore lysis of multiple myeloma cells and therefore holds potential as a treatment for patients with multiple myeloma.

08:10 EST BeyondSpring presents plinabulin data in DIN in NSCLC patients - BeyondSpring announced data from the ESMO Asia Congress 2022 and the American Society of Hematology Annual Meeting about the use of lead asset, plinabulin, for the prevention of docetaxel-induced neutropenia in non-small cell lung cancer patients. In addition, data was presented on plinabulin for the prevention of docetaxel-induced neutropenia in breast cancer at the 2022 San Antonio Breast Cancer Symposium. The analyses in the NSCLC studies support the efficacy of plinabulin as a monotherapy in reducing the mean duration of severe neutropeniawith a greater than1 day benefit for patients receiving docetaxel and plinabulin in two independent randomized trials. Title: Prevention of Docetaxel Induced Neutropenia with Single Agent Plinabulin Versus Control in Non-Small Cell Lung Cancer in Two Randomized Trials: The presentation summarized data from two randomized NSCLC studies, and DIN results were compared between the plinabulin arm and the control arm. The DSN was calculated based on Day 8 absolute neutrophil count values in the plinabulin and control arms. In NSCLC patients, docetaxel 75 mg/m2 is typically used without G-CSF prophylaxis. This analysis focuses on the effectiveness of plinabulin vs. control for the prevention of DIN in the 101 and 103 studies. In summary, in these two independent randomized studies, plinabulin demonstrated a superior benefit for Gr4N, Gr3/4N, all GrN and DSN compared to the control. Importantly, in both these randomized studies, there was a reduction in mean DSN of greater than1 day for plinabulin vs. control. Title: Superior single agent effectiveness with plinabulin versus placebo for docetaxel-induced neutropenia prevention in non-small cell lung cancer patients: The presentation summarized DIN data from a non-randomized comparison derived from two different studies: plinabulin data from study 105 and the control data from study 103. In the 105 study, NSCLC pts with at least one febrile neutropenia risk factor received docetaxel 75 mg/m2 with plinabulin. In the 103 study, patients received docetaxel 75 mg/m2 without plinabulin. In summary, plinabulin was superior for the prevention of DIN and hematologic complications vs control: Grade 4 Neutropenia: 17% with plinabulin vs 40% with placebo. In addition, the mean DSN was 0.43 days for plinabulin vs. 1.32 days for placebo. There was also a favorable quality of life and safety profile with plinabulin. Title: Superior effectiveness of Plinabulin versus no-treatment for Docetaxel-induced neutropenia and other hematologic complication in breast cancer patients: The presentation summarized DIN data for plinabulin from study 105 and the control data was taken from the literature. The hematologic complications endpoints from the 27 early breast cancer patients with at least one NCCN high FN risk factor from the Phase 3 portion of 105 study were compared with the no-treatment studies from literature where patients were given 75 mg/m2 docetaxel without G-CSF. Blood sampling in the no-treatment studies were infrequent and likely underestimated the true grade 4 neutropenia frequency. In summary, despite a higher frequency of ANC sampling in cycle 1, plinabulin was superior vs no-treatment for DIN and hematologic complications. Quality of life was maintained, and there were minimal adverse effects including minimal bone pain burden in the plinabulin arm vs. no-treatment.

08:09 EST MAIA Biotechnology expands Phase 2 THIO-101 trial to Europe - MAIA Biotechnology announced that regulatory authorities in three European countries, Hungary, Poland, and Bulgaria, have approved the implementation of THIO-101, MAIA's Phase 2 clinical trial evaluating its lead therapeutic candidate, THIO, in patients with Non-Small Cell Lung Cancer NSCLC. The first patients in THIO-101 were dosed in Australia earlier this year. THIO-101 is designed to evaluate THIO's potential immune system activation effects in NSCLC patients by administering THIO in advance of administration of Regeneron's anti-PD1 therapy, Libtayo or cemiplimab , allowing for immune system activation and sensitivity to the PD-1 inhibitor to take effect. The primary objectives of the trial are to evaluate the safety and tolerability of THIO administered as a direct anticancer and priming immune system agent prior to cemiplimab administration, as well as to evaluate the clinical efficacy of THIO in patients with advanced NSCLC who either progressed or relapsed through treatment with an immune-check point inhibitor alone or in combination with chemotherapy. "Adding EU sites to the THIO-101 study increases patient access to THIO on a global scale. Lung cancer is the second most common cancer indication, so addressing it requires worldwide research efforts," said MAIA Chief Medical Officer Mihail Obrocea, M.D. "Adding EU sites to THIO-101 officially makes it a global trial. We believe the data that THIO-101 generates will further validate THIO and be a major step towards bringing effective therapies to lung cancer patients."

08:07 EST Immix Biopharma announces patient dosing in Phase 1b/2a IMX-110 trial - Immix Biopharma announced patient dosing in its ongoing Phase 1b/2a IMX-110 monotherapy clinical trial. This is the fifteenth patient dosed with IMX-110 to-date. IMX-110 clinical trial data is expected to be released on a rolling basis beginning in Q1 2023; once dosing begins, patients undergo CT scans every 8 weeks to assess tumor response to IMX-110. IMX-110 monotherapy and IMX-110 combination clinical trial with Beigene/Novartis anti-PD-1 tislelizumab are enabled by newly manufactured, scaled-up IMX-110 GMP batches produced using our proprietary process. "We are thrilled to accelerate our efforts to bring IMX-110 to patients after scaling-up manufacturing of IMX-110," said Ilya Rachman, MD PhD, CEO of ImmixBio. "Key opinion leaders at our 5 clinical trial sites are excited to bring IMX-110 to their adult and pediatric cancer patients as a monotherapy and as a combination with Beigene/Novartis anti-PD-1 tislelizumab."

08:05 EST BAE Systems signs two contracts worth $32M for Bofors 57mm ammunition - BAE Systems has signed two contracts worth approximately $32M for its market-leading Bofors 57mm 3P advanced ammunition in a combined procurement from both the Swedish Defence Materiel Administration, or FMV, and the Finnish Defence Forces Logistics Command, or FDF LOG COM. Sweden is ordering a large stock of the Bofors 57mm 3P advanced ammunition, for an order value of approximately $18M. This is a critical step for the Swedish Armed Forces as they continue their efforts to increase readiness in the face of the current security situation in Central Europe. The FMV also has a contract option for additional quantities in 2023. Finland is also ordering a considerable stock of rounds of the ammunition, valued at approximately $14 million. This is an important step in reinforcing the security of supplies as Finland, and in particular the Finnish Navy, also confirms its readiness.

08:03 EST Mullen Automotive signs first U.S. dealer partner, Randy Marion Automotive - Mullen Automotive announces Randy Marion Automotive as the first dealer group partner for Mullen's commercial EV lineup, which is set to launch in the U.S. in 2023. Mullen's commercial EV lineup includes Class 1-3 cargo van and cab chassis offerings and Bollinger Motors Class 4-6 chassis products. "We are excited to bring on such a tremendous dealer partner that is so well respected and recognized throughout the commercial industry," said David Michery, CEO and chairman of Mullen Automotive. "Randy and his team recognize the opportunity with Mullen's commercial vehicles and are poised to be a critical partner for us."

08:02 EST Leidos selected to upgrade Atlanta International Airport's security checkpoints - Leidos was selected by New-South Synergy to upgrade U.S. Transportation Security Administration checkpoints at Hartsfield-Jackson Atlanta International Airport. The upgrades are part of a larger initiative to expand and enhance the airport's security checkpoints by leveraging the latest technologies, while also improving the passenger experience. The upgrade will update security lanes at the Domestic Terminal Main Security Checkpoint with Leidos' Advanced Imaging Technology.

08:01 EST WEC Energy plans to raise quarterly dividend 7.2% in 1Q23 - The board of directors of WEC Energy Group announced that it is planning to raise the quarterly dividend on the company's common stock to 78c per share in the first quarter of 2023. This would represent an increase of 5.25c per share, or 7.2%. The directors expect to declare the new dividend at their regularly scheduled meeting in January. The dividend - which would be equivalent to an annual rate of $3.12 per share - would be payable March 1, 2023, to stockholders of record on Feb. 14, 2023.

07:49 EST Cornerstone files management information circular for SolGold arrangement - Cornerstone Capital Resources announced that it has filed and commenced mailing its management information circular and related materials in connection with the special meeting of Cornerstone shareholders to be held in virtual-only format via live webcast at 9:00 a.m. on January 9, 2023 to approve the previously-announced plan of arrangement with SolGold, all as more particularly described in the Circular.The Circular provides important information regarding the Arrangement and related matters, including the background to the Arrangement, the reasons for unanimous recommendation of the board of directors of Cornerstone, voting procedures and how to virtually attend the Meeting. Shareholders are urged to read the Circular and its appendices carefully and in their entirety. The Circular and the related materials in connection with the Meeting are being mailed to Shareholders in compliance with applicable laws and interim order of the Court of King's Bench of Alberta granted on December 6, 2022 and are available under Cornerstone's issuer profile on SEDAR at www.sedar.com. The Board of Directors unanimously recommends that the Shareholders vote FOR the Arrangement. Since announcement of the Arrangement, SolGold has raised gross proceeds of US$86M through royalty and equity financings. SolGold is well positioned to advance the ongoing strategic review process while continuing to advance and de-risk the world class Cascabel project. In connection with SolGold's upcoming annual general meeting, not in connection with the Arrangement, to be held on December 22, 2022, Cornerstone is pleased to report that it has voted FOR all resolutions proposed to be approved by SolGold shareholders.

07:47 EST Jacobs providing consulting services to US air bases in Japan - Jacobs was selected to provide professional facility planning, programming, design and construction management services for the U.S.Air Force at Yokota Air Base, Misawa Air Base and Camp Zama, Japan. This indefinite delivery indefinite quantity architecture and engineering services contract for the USAF 374th Airlift Wing, Yokota Air Base, Japan has a shared potential ceiling across multiple awardees of $99M. The contract has an initial five-year base period with the option to renew for an additional two years.

07:46 EST Cellectis announces preliminary data for UCART22, UCART123 - Cellectis will host a live webcast reviewing updated clinical data on its Phase 1/2a BALLI-01 clinical trial and on its Phase 1 AMELI-01 clinical trial that were presented in an oral session on December 12, 2022 at the 64th Annual Meeting of the American Society of Hematology, ASH. BALLI-01 is a Phase 1/2a open-label dose-escalation trial evaluating the safety and clinical activity of UCART22 given at escalating dose levels after lymphodepletion with either fludarabine and cyclophosphamide or FC with alemtuzumab in patients with relapsed or refractory acute lymphoblastic leukemia. Alemtuzumab was added to the LD regimen to sustain host T-cell and Natural Killer cell depletion and to promote UCART22 cell expansion and persistence. Compared to the last clinical update on BALLI-01 at ASH 2021, the webcast presented data from five additional patients who received UCART22 at dose level 3 5x106 cells/kg after lymphodepletion with FCA. No dose limiting toxicities, Grade 2 or higher cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome or adverse events of special interest were observed. Evidence of UCART22 anti-tumor activity was observed in 60% (n=3) of the five patients at DL3 after lymphodepletion with FCA: A patient experienced a durable minimal residual disease negative complete response with incomplete count recovery that continues beyond 6 months. A patient experienced an MRD negative complete response that continues beyond Day 56. A patient experienced a morphologic leukemia-free state that continues beyond Day 84. All three of the responders failed multiple lines of prior therapy including chemotherapy, CD19-directed autologous CAR T cell therapy, and allogeneic stem cell transplant. Additionally, the patient with the MRD negative CR also failed both prior blinatumomab and inotuzumab. Overall, these preliminary data support the continued administration of UCART22 after FCA lymphodepletion in patients with r/r ALL. The Company is now enrolling patients in BALLI-01 with product candidate manufactured fully in-house at DL2 after FCA lymphodepletion. The first patient has been dosed at dose level 2 1x106 cells/kg. The next data set is expected to be released in 2023.

07:42 EST Jushi Holdings unveils cannabis brand portfolio in California - Jushi Holdings announced the launch of a comprehensive product suite in California that includes three brands crafted to meet cannabis consumers' preferences and price points. With the addition of Seche Pre-Roll Singles, Tasteology Fruit Chews and The Lab Vapes, the Company brings a new selection of high-quality brands and proprietary products exclusively available at the Company's Beyond Hello retail locations in the Golden State. "As California is one of the most competitive and mature cannabis markets in the world, California cannabis consumers have some of the most discerning tastes," said Jim Cacioppo, CEO. "They want high-quality products at a range of price points that deliver a premium consumer experience. Our diverse house of brands has been carefully crafted to meet the needs of the canna-curious and the canna-connoisseurs alike. As we expand Jushi's branded product portfolio in key markets across the country, we look forward to exceeding consumers expectations by offering new, innovative brands and products through our digital and retail store footprint."

07:40 EST Innovation Pharmaceuticals reports in vivo antifungal data on Brilacidin - Innovation Pharmaceuticals provided an update on ongoing research on the broad-spectrum antifungal activity of Brilacidin, the Company's defensin mimetic drug candidate exhibiting antimicrobial and immunomodulatory properties. New in vivo data in an A. fumigatus murine fungal keratitis model showed Brilacidin reduced fungal burden and disease severity, while also improving corneal thickness compared to control. Brilacidin-treated corneas harbored almost no viable fungus, suggesting the compound suppressed fungal proliferation within the cornea. Worldwide, on an annual basis, fungal keratitis affects up to 1.5 million people, of whom 75 percent may lose an eye and/or their sight. These new Brilacidin findings in fungal keratitis complement an earlier in vitro and in vivo evaluation of Brilacidin as an ocular anti-infective in bacterial keratitis. A broad-spectrum drug that could target both fungal and bacterial keratitis would be uniquely positioned as to its treatment profile and commercial potential. Planned next steps in Brilacidin antifungal research include extending in vitro and in vivo testing into additional clinical isolates and animal models, and publishing scientific findings. In collaboration with the NIH/NIAID's mycology division, Brilacidin also is to be screened in multiple fungal species to further characterize its broad-spectrum antifungal activity. Future updates are planned.

07:40 EST Amedisys closes on home health JV with University of Arkansas - Amedisys has closed on its joint venture with the University of Arkansas for Medical Sciences to provide home health services in Searcy and Little Rock. This joint venture is part of the partnership between UAMS, Amedisys and Contessa, an Amedisys company, to offer patients a full spectrum of medical care in the comfort and convenience of their own homes through UAMS Health Comprehensive Care at Home. Clinical services will include Recovery Care at Home, Rehabilitation Care at Home, Palliative Care at Home, Primary Care at Home and Home Health. Home health services include skilled nursing care; physical, occupational and speech therapy; medical social work; and home health aides to assist with activities of daily living, such as bathing, dressing and eating. Home health services will operate as UAMS Health Home Health across 12 counties in Central Arkansas.

07:39 EST Arbutus Biopharma completes enrollment in Phase 2 trial with AB-729, NA therapy - Arbutus Biopharma announced preliminary data from the AB-729 lead-in portion of its Phase 2a clinical trial combining AB-729 with nucleos(t)ide analogue therapy and Peginterferon alfa-2a. The data reinforces AB-729's surface antigen reducing-capacity, while continuing to exhibit a generally safe and well-tolerated profile in patients with chronic Hepatitis B virus. Given that only a few patients are in the early weeks of the IFN phase of the clinical trial, the Company intends to provide additional updated data in the first half of next year which will include preliminary results of the IFN portion of the trial. Enrollment is complete in the clinical trial with 43 patients having received at least one dose of AB-729. For the first 15 patients who reached week 16 of treatment and received two doses of AB-729 plus NA therapy, the mean HBsAg decline was 1.51 log, comparable to the decline observed at the same timepoint in the completed Phase 1b clinical trial AB-729-001. As the trial progresses, patients will be randomized into various treatment arms which include the combination of AB-729, NA therapy and short courses of IFN for either 12 or 24 weeks. The randomized, open label, multicenter Phase 2a proof-of-concept clinical trial is designed to investigate the safety and antiviral activity of AB-729 in combination with ongoing NA therapy and short courses of IFN. After completion of the assigned IFN treatment period, all patients will remain on NA therapy for an additional 24-weeks and will then discontinue NA treatment provided they meet pre-defined stopping criteria. Patients who stop NA therapy will enter an intensive follow-up period of 48 weeks.

07:38 EST MeiraGTx announces clinical data from the AQUAx Phase 1 study of AAV2-hAQP1 - MeiraGTx announced positive clinical data from the ongoing Phase 1 AQUAx study of AAV2-hAQP1 for the treatment of grade 2/3 radiation-induced xerostomia. AQUAx is an open label, multi-center, dose escalation study of a single administration of AAV2-hAQP1 to one or both parotid glands in patients with radiation-induced salivary hypofunction and grade 2/3 xerostomia. As of the cutoff date of November 30, 2022, all 12 unilaterally treated participants have undergone their 12-month assessment, with 3 having completed their 24-month assessment and one having completed their 36-month assessment in the long-term follow-up study. Efficacy Data presented from the 24 participants treated in the AQUAx study: Clinically meaningful improvements in xerostomia symptoms reported consistently across two validated PROs assessing xerostomia symptom severity; Meaningful increases in whole saliva flow rates observed post-treatment, providing objective evidence of biological activity of AAV2-hAQP1 treatment; Early long-term follow-up data suggest durability of improvement 2+ years post-treatment. Global Rate of Change: Bilateral Cohorts to 6 Months: 10/12 participants reported symptoms of dry mouth as "better" at the 6 month timepoint; No participant reported any worsening of xerostomia symptoms. Unilateral Cohorts to 12 Months: 8/12 participants who reached the 12-month assessment reported symptoms of dry mouth as "better" following treatment; Improvement in xerostomia symptoms can be seen persisting through 2 years in all 3 patients who have reached that timepoint; Participant 1-1 reached the 3-year assessment and the maximum score of 7 was maintained; No participant reported any worsening of xerostomia symptoms. Combined Unilateral and Bilateral Cohorts: 18/24, or 75%, of all unilateral and bilateral treated participants reported symptoms of dry mouth as "better" following treatment; In the overall cohorts the average improvement in scores was greater in bilateral participants compared to unilateral participants; Unilateral cohort achieved overall improvement of greater than3 points at 12 months; Bilateral cohort achieved overall improvement of greater than3 points at 2 months and an overall improvement of 4 points by 6 months; overall improvement in scores was maintained and increased over time in both unilateral and bilateral cohorts

07:35 EST Indaptus Therapeutics initiates first-in-human Phase 1 trial of Decoy20 - Indaptus Therapeutics announces the initiation of INDP-D101, its first-in-human, open label, dose escalation and expansion, multicenter Phase 1 clinical trial of its lead compound Decoy20 in patients with advanced/metastatic solid tumors. The USC Norris Cancer Center in Los Angeles, California is the first activated clinical trial site that has been opened for patient enrollment, and patient screening is expected soon. The study's objectives are to assess the safety and tolerability of Decoy20, to determine the maximum tolerated dose and recommended phase 2 dose, as well as to assess Decoy20 pharmacokinetics, pharmacodynamics and clinical activity. The Phase 1 study will begin with a single dose escalation part followed by an expansion part with continuous administration of Decoy20. The study will enroll patients with advanced/metastatic solid tumors, who have exhausted the other known treatment options. Primary endpoint of the study is incidence, relatedness and severity of adverse events and treatment-emergent adverse events and determining the number of subjects per cohort with dose limiting toxicity-based adverse events. Secondary endpoints include the incidence of anti-drug antibodies and neutralizing antibodies pre- and post-treatment, change in Decoy20 PK parameters over time, objective response rate in subjects with measurable disease and duration of response.

07:34 EST Wave Life Sciences, GSK collaborate for oligonucleotide therapeutic development - Wave Life Sciences Ltd. (WVE) and GSK (GSK) announced a strategic collaboration to advance oligonucleotide therapeutics, including Wave's preclinical RNA editing program targeting alpha-1 antitrypsin deficiency, WVE-006. The discovery collaboration has an initial four-year research term. It combines GSK's unique insights from human genetics, as well as its global development and commercial capabilities, with Wave's proprietary discovery and drug development platform, PRISM(TM). Oligonucleotides are short strands of DNA or RNA that can reduce, restore, or modulate RNA through several different mechanisms. The unique capability of oligonucleotides to address a wide range of genomic targets in multiple therapeutic areas is enabling new opportunities to treat a range of human diseases, including diseases where no medicines currently exist or that have historically been difficult to treat with small molecules or biologics. Wave's PRISM platform is the only oligonucleotide platform offering three RNA-targeting modalities. Importantly, these modalities incorporate novel chemistry, including PN backbone chemistry and control of stereochemistry, to optimize the pharmacological properties of therapeutic oligonucleotides.The collaboration includes two main components. The first is a discovery collaboration which enables GSK to advance up to eight programs and Wave to advance up to three programs, leveraging Wave's PRISM platform and GSK's expertise in genetics and genomics. In addition to these programs, GSK receives the exclusive global license for Wave's preclinical program for AATD called WVE-006, which uses Wave's proprietary "AIMer" technology. AATD is an inherited genetic disease that affects both the lungs and liver with limited treatment options. Wave's WVE-006 is a first-in-class RNA editing therapeutic that is designed to address both liver and lung manifestations of the disease. Bepirovirsen, an investigational antisense oligonucleotide for the potential treatment of chronic hepatitis B infection, is now entering Phase III trials, and GSK4532990, a siRNA oligonucleotide, is progressing to Phase II for NASH. WVE-006 brings a third oligonucleotide into GSK's portfolio that has the potential to be a first-in-class AATD treatment for both lung and liver disease and is a well-understood genetic target, contributing to GSK's pipeline that is now more than 70% genetically validated. The companies expect to pursue targets across multiple disease areas, given preclinical data indicating Wave oligonucleotides can distribute to various tissues and cells without complex delivery vehicles.Under the terms of the agreement, Wave will receive an upfront payment of $170M, which includes a cash payment of $120M and a $50M equity investment. For the WVE-006 program, Wave is eligible to receive up to $225M in development and launch milestone payments and up to $300M in sales-related milestone payments, as well as tiered sales royalties. Development and commercialization responsibilities will transfer to GSK after Wave completes the first-in-patient study. For each of GSK's eight collaboration programs, Wave will be eligible to receive up to $130-$175M in development and launch milestones and $200M in sales-related milestones, along with tiered sales royalties. Wave will lead all preclinical research for GSK and Wave programs up to investigational new drug enabling studies. GSK collaboration programs will transfer to GSK for IND-enabling studies, clinical development, and commercialization. The collaboration includes an option to extend the research term for up to three additional years, expanding the number of programs available to both parties. The equity investment and collaboration agreement will complete at the same time and are conditional upon customary conditions including regulatory review by the appropriate regulatory agencies under the Hart-Scott-Rodino Act.

07:28 EST Denbury announces new CO2 sequestration site in SW Louisiana - Denbury announced a definitive agreement with a large landowner in southwest Louisiana for the future development and operation of a dedicated CO2 sequestration site. The 31,000 acre land position is located in Allen, Beauregard and Vernon Parishes, approximately 25 miles north of Denbury's Green Pipeline. Denbury estimates that there is potential to store up to 250 million metric tons of CO2 in the site, with first injection planned as early as 2026. The strategic location of the site provides nearby storage potential for the heavy industrial areas of Beaumont and Port Arthur, Texas, and Lake Charles, Louisiana. In close proximity to the dedicated CO2 sequestration site is more than 60 million metric tons per year of existing emissions. Nik Wood, Denbury's Senior Vice President, CCUS, commented, "Denbury has unparalleled experience and CO2 pipeline infrastructure in the U.S. Gulf Coast for the transportation and storage of CO2. Today's announcement adds an important piece in the development of our CCUS business, providing another significant future storage site in close proximity to our pipeline infrastructure, which naturally expands the reliability and future capacity of our network. We look forward to developing this site as we aim to provide the most efficient and reliable CO2 platform in the U.S."

07:25 EST JetBlue sees Q4 revenue per ASM at low end of 15%-19% range

07:24 EST JetBlue still sees Q4 flown capacity up 1%-4% vs. 3Q19 - In a regulatory filing, JetBlue said its operational performance has remained strong with a solid completion factor quarter-to-date, including nearly 100% during the November holiday travel period. The company continues to expect flown capacity for the fourth quarter of 2022 to increase 1% to 4% compared to the third quarter of 2019. Underlying demand trends continue to be strong with healthy load factors and yields above 2019 levels for both trough and peak travel periods. JetBlue also continues to generate strong ancillary revenue performance, with exceptional co-brand performance which continues to reach record levels. However, JetBlue experienced a negative impact from Hurricane Nicole in November, and the expected very strong close-in demand for December reflected in its prior outlook has materialized below expectations. In addition, the adverse impact of the fourth quarter holiday calendar timing this year is greater than previously forecasted. As a result, JetBlue now expects revenue per available seat mile for the fourth quarter of 2022 to be at the low-end of its prior guidance range for a 15% to 19% increase. The company continues to expect CASM Ex-Fuel for the fourth quarter of 2022 to increase between 8.5% and 10.5%, year over three. Based on the forward curve as of December 9, 2022, JetBlue continues to expect an average all-in price per gallon of fuel of $3.65 in the fourth quarter of 2022.

07:20 EST Quanergy initiates sale process through Chapter 11, CEO Kevin Kennedy to retire - Quanergy announced that the company initiated an orderly sale process for its business. To facilitate the sale and maximize value, the company filed for protection under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware and intends to pursue a sale of the business under section 363 of the Bankruptcy Code. Quanergy also announced that Kevin Kennedy, CEO, will retire effective December 31, but will continue to serve as non-executive chair of the board of directors. Kennedy will transition executive leadership to a newly appointed chief restructuring officer and president, Lawrence Perkins. Perkins is the founder and CEO of SierraConstellation Partners, an interim management and advisory firm, which he founded in 2013. Perkins has served in a variety of senior-level positions, including interim CEO/President, chief restructuring officer, board member, financial advisor, strategic consultant, and investment banker, to numerous private and public middle-market companies. Prior to the filing of the company's Chapter 11 case, the board of directors and management evaluated a wide range of strategic alternatives to maximize value for all stakeholders. The company also significantly reduced operating expenses and resolved significant patent litigation with Velodyne. Now with the protections afforded by the Bankruptcy Code, the company intends to broaden its marketing efforts to potential purchasers interested in specific business segments or assets as well as continuing to seek a going concern sale of the business. The company expects to continue operations during the Chapter 11 process and seeks to complete an expedited sale process with Bankruptcy Court approval. To help fund and protect its operations, Quanergy intends to use available cash on hand along with normal operating cash flows to fund post-petition operations and costs in the ordinary course.

07:18 EST Iris Energy reports 151 bitcoin mined in November - Iris Energy published a monthly investor update for November 2022, containing its results from operations as well as construction and development updates. Corporate: Liquidity: $47 million cash, no debt; $21 million estimated net capex spend to achieve 180MW5; $75 million remaining Bitmain prepayments; $100 million unutilized under B. Riley equity facility; Potential monetization of assets through miner sales. Opportunities: Significant optionality from 180MW real assets platform; Focus on expanding self-mining capacity to 5.4 EH/s; Potential additional expansion from 20MW to 600MW at Childress. On November 21, the Company also provided a corporate update and announced certain preliminary financial information and operational updates for Q1 FY23 and October 2022. Operations: Average operating hashrate of 1,445 PH/s; Monthly operating revenue of $2.9 million; 151 Bitcoin mined.

07:17 EST Moderna, Merck report personalized mRNA cancer vaccine trial met trial endpoint - Moderna (MRNA) and Merck (MRK) announced that the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial of mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with Keytruda, Merck's anti-PD-1 therapy, demonstrated a "statistically significant and clinically meaningful" improvement in the primary endpoint of recurrence-free survival, or RFS, versus Keytruda alone for the adjuvant treatment of patients with stage III/IV melanoma following complete resection. Adjuvant treatment with mRNA-4157/V940 in combination with Keytruda reduced the risk of recurrence or death by 44% compared with Keytruda alone. Adverse events observed with mRNA-4157/V940 in KEYNOTE-942 were consistent with those previously reported in a Phase 1 clinical trial. The safety profile of KEYTRUDA was consistent with that observed in previously reported studies. Serious treatment-related adverse events occurred in 14.4% of patients who received the combination arm of mRNA-4157/V940 and KEYTRUDA versus 10% with KEYTRUDA alone. The companies plan to discuss the results with regulatory authorities and initiate a Phase 3 study in melanoma patients in 2023. In October of this year, the companies announced that Merck had exercised its option to jointly develop and commercialize mRNA-4157/V940. Merck and Moderna will share costs and any profits equally under this worldwide collaboration. "Today's results are highly encouraging for the field of cancer treatment. mRNA has been transformative for COVID-19, and now, for the first time ever, we have demonstrated the potential for mRNA to have an impact on outcomes in a randomized clinical trial in melanoma. We will begin additional studies in melanoma and other forms of cancer with the goal of bringing truly individualized cancer treatments to patients. We look forward to publishing the full data set and sharing the results at an upcoming oncology medical conference, as well as with health authorities," said Stephane Bancel, Moderna's CEO.

07:15 EST MCI Onehealth announces consolidation of certain Ontario clinics - MCI Onehealth Technologies announced that it is consolidating certain Ontario clinics within its high-performance healthcare network. The consolidation is expected to enable extended hours at remaining clinics, enable intensification of services and significantly reduce overhead costs. Consolidated MCI clinics will cease operations under MCI management in the Company's fourth quarter of 2022, with the majority of physicians, nurses and staff expected to be redeployed at remaining MCI clinics. Ontario and Alberta clinics that operate as MCI The Doctor's Office will continue to provide top-quality, accessible walk-in, family practice and specialist care to MCI's clientele of more than one million patients. The five MCI The Doctor's Office clinics in Alberta are not participating in the consolidation. "MCI has made the strategic decision to consolidate five under-capacity clinics into its remaining 15 Ontario clinics where possible. We fully expect that this action will have a positive impact on the financial performance of the Company and enable the Company to remain focused on sustained growth in its higher-margin, data-driven and clinical research initiatives." said Scott Nirenberski, MCI Onehealth CFO.

07:12 EST Fluence Energy to design, manufacture battery packs as part of storage products - Fluence Energy announced a strategic plan to develop Fluence-made battery packs, with production set to begin in early 2024 in the United States. The move is intended to give Fluence greater control over the global supply chain and increase standardization across products. The Fluence-designed pack will include battery modules and a battery management system with cells procured competitively from our growing base of global suppliers. "This strategic move to develop the Fluence battery pack is possible because of the deep technical expertise within our research and development team," said Fluence SVP and Chief Product Officer Rebecca Boll. "This program is the next pivotal step for Fluence's supply chain flexibility. The Fluence-developed BMS allows for the rapid acceleration of our cloud-based software products and aftermarket services growth, all while providing increased standardization across our storage products." Fluence is working closely with suppliers to secure a globally-diversified battery cell supply and will procure cells competitively for our battery packs. Fluence will also incorporate its own BMS technology into the packs to enhance access to granular data and system control, while expanding battery intelligence capabilities.

07:10 EST Freight Technologies' platform Fr8App integrates with FourKites - Freight Technologies discloses its integration with FourKites, a leading supply chain visibility platform in the U.S. With this integration, Fr8App's platform can send automatic locations to the FourKites's New Unified Customer Interface so that enterprise companies using the new FourKites's product are able to receive real time locations from drivers using Fr8App. "A leader in track and trace in the U.S., FourKites is used by many enterprise companies and some of our current customers. With this integration we empower our Fr8Radar product, making the track and trace monitoring process more efficient for our customers currently using FourKites's monitoring system," said Javier Selgas, CEO of Fr8Tech. "By integrating with Fr8App, FourKites has validated our services and increased our access to new, large customers. We believe this alliance will be a long-term revenue driver and we look forward to reporting on our progress."

07:09 EST Highwoods Properties, The Bromley Companies form 50/50 joint venture - Highwoods Properties and The Bromley Companies have formed a 50/50 joint venture to construct Midtown East, a multi-customer office development project located in the mixed-use Midtown Tampa project in Tampa's Westshore submarket. Upon completion, the joint venture will own 134,000 square feet, consisting of five floors of office and ground level retail, of an overall 18-story, 432,000 square foot tower. The total anticipated investment for the joint venture's share of the overall project is approximately $83M. Construction of the project is expected to begin in the first quarter of 2023 with a scheduled completion date in the first quarter of 2025 and a pro forma stabilization date in the second quarter of 2026. Highwoods currently owns an 80% interest in a joint venture with The Bromley Companies that developed and owns Midtown West, a 150,000 square foot, $71 million office project completed in the second quarter of 2021 that was 92.5% leased as of September 30, 2022. Ted Klinck, President and Chief Executive Officer of Highwoods, said, "We're excited to once again partner with The Bromley Companies on another high-quality office development in the dynamic Midtown Tampa district. The proven success of Midtown West, which broke ground in the fourth quarter of 2019 and leased up according to pro forma even in the midst of a global pandemic, has demonstrated how quickly Midtown Tampa has become the premier office destination for growing companies in Tampa."

07:07 EST Takeda to acquire NDI-034858 from Nimbus Therapeutics for $4B upfront - Takeda announced that it will acquire NDI-034858 from Nimbus Therapeutics. NDI-034858 is an oral, selective allosteric tyrosine kinase 2, or TYK2, inhibitor being evaluated for the treatment of multiple autoimmune diseases following successful recent Phase 2b results in psoriasis. When the transaction is complete, NDI-034858 will be known as TAK-279. Nimbus recently disclosed positive topline results from a Phase 2b study evaluating NDI-034858 in patients with moderate-to-severe plaque psoriasis. Takeda intends to present results from this Phase 2b study early in 2023. NDI-034858 is anticipated to enter Phase 3 in psoriasis in 2023. It is in an ongoing Phase 2b study in active psoriatic arthritis, and Takeda plans to investigate it for the treatment of IBD and other autoimmune diseases. Under the terms of the agreement, Takeda will pay Nimbus $4B upfront, and two milestone payments of $1B each upon achieving annual net sales of $4B and $5B. The upfront payment will be primarily funded by cash on hand. The transaction is expected to be finalized before the end of FY22. Closing of the transaction is contingent on completion of review under antitrust laws, including the Hart-Scott-Rodino Antitrust Improvements Act of 1976.

07:05 EST Bausch + Lomb's Biotrue contact lense cleaner receives 510(k) clearance from FDA - Bausch + Lomb has received 510(k) clearance from the FDA for Biotrue Hydration Boost Contact Lens Rehydrating drops, a preservative-free multi-dose rehydrating drop for use with soft and rigid gas permeable contact lenses. Biotrue Hydration Boost Contact Lens drops contain a combination of ingredients informed by the Tear Film and Ocular Surface Society's DEWS II report including hyaluronan, a moisturizer found naturally in the eye, and other naturally inspired ingredients. Biotrue Hydration Boost for Contacts also matches the pH of healthy tears for comfort.

07:05 EST EVgo, Lyft launch new partnership to accelerate rideshare electrification - EVgo (EVGO) announced the launch of a new EV charging discount program for rideshare drivers on the Lyft (LYFT) platform. Starting this week, drivers on the Lyft platform will be able to enroll in the new program with EVgo via the Lyft Driver app. Once enrolled, drivers in certain markets with Lyft Gold and Platinum status can save up to 45% on session costs over EVgo's standard Pay As You Go rates. In addition, drivers with Lyft will enjoy waived monthly fees at EVgo's more than 850 fast charging locations nationwide.

07:03 EST Cytokinetics announces Nasdaq halts trading of stock - Cytokinetics, Incorporated announced that Nasdaq has halted the trading of the Company's common stock. The U.S. Food & Drug Administration Cardiovascular and Renal Drugs Advisory Committee is meeting to review the New Drug Application for omecamtiv mecarbil, an investigational selective, small molecule cardiac myosin activator for the treatment of heart failure with reduced ejection fraction. The advisory committee meeting, which is being held virtually, is scheduled to begin at 9:00 AM.The Company is not responsible for the content of, nor the statements made in, the briefing materials that were prepared by the FDA. The NDA for omecamtiv mecarbil is based on the results from GALACTIC-HF, the Phase 3 clinical trial of omecamtiv mecarbil. The Prescription Drug User Fee Act target action date for the NDA is February 28, 2023.

07:02 EST AirSculpt Technologies to open London location in 2023 - AirSculpt Technologies announced the opening of its first overseas Elite Body Sculpture location in London, England in the first half of 2023. AirSculpt now expects to open five office locations in 2023.

06:47 EST TransUnion to sell G2, LCI and Fintellix for $176M - TransUnion has signed a definitive agreement to sell G2 Web Services, Lundquist Consulting - LCI - and Fintellix India, to an affiliate of Stellex Capital, a global, multi sector investment firm with offices in New York, Detroit, Pittsburgh and London with over $2.6B in AUM. The $176M consideration consists of $104M of cash and a $72M note receivable with up to three years in duration. The companies are targeting to close the transaction by the end of the year. TransUnion expects to use the net cash proceeds to pre-pay debt. TransUnion acquired Verisk Financial Services in April 2022 for $515M for its proprietary database of card and deposit transactions, and related advisory services.

06:33 EST United orders 100 Boeing 787 Dreamliners, includes option to purchase 100 more - United Airlines (UAL) announced the largest widebody order by a U.S. carrier in commercial aviation history: 100 Boeing (BA) 787 Dreamliners with options to purchase 100 more. United expects to take delivery of the new widebody planes between 2024 and 2032 and can choose among the 787-8, 9 or 10 models, providing flexibility to support a wide range of routes. United also exercised options to purchase 44 Boeing 737 MAX aircraft for delivery between 2024 and 2026 - consistent with the United Next 2026 capacity plan - and ordered 56 more MAX aircraft for delivery between 2027 and 2028. The airline now expects to take delivery of about 700 new narrow and widebody aircraft by the end of 2032, including an average of more than two every week in 2023 and more than three every week in 2024. United also will retrofit 100% of its mainline, narrow-body planes with its signature interior - about 100 aircraft are scheduled to be completed in 2023 with the remaining expected to be completed by the end of 2025. Approximately 100 planes of the new widebody order are expected to replace older Boeing 767 and Boeing 777 aircraft, with all 767 aircraft removed from the United fleet by 2030, resulting in up to an expected 25% decrease in carbon emissions per seat for the new planes compared to the older planes they are expected to replace.

06:32 EST Babcock & Wilcox awarded $20M contract for ash-handling technologies - Babcock & Wilcox's B&W Environmental segment has been awarded a contract for more than $20M to design and supply ash-handling and conveying technologies for a power plant in North America. The equipment is designed to assist the plant operator to reduce the environmental impact of the plant and compliance with emissions regulations. The SGC systems will be manufactured in B&W's Lancaster, Ohio, facility.

06:08 EST Secoo Holding regains compliance with Nasdaq minimum bid price requirement - Secoo Holding has received a written notification letter from the Listing Qualifications Department of Nasdaq dated December 12 informing the company that it has regained compliance with Nasdaq's Minimum Bid Price Requirement. The closing bid price of the company's ADSs has been at $1.00 per ADS or greater for 10 consecutive business days from November 28 to December 9, and the matter is closed.

06:06 EST Rockwell Medical adds hemodialysis business in Minnesota - Rockwell Medical is adding new business within the Minnesota region. Rockwell started to supply these clinics with its hemodialysis concentrates products effective December 5, anticipates that all clinics will be onboarded by January 1, 2023, and expects to generate over $1M in revenue the first year. In the U.S., the in-center hemodialysis concentrates market is currently valued at $380M and is anticipated to grow to approximately $500M by 2026, driven primarily by an increasing number of patients suffering from end-stage kidney disease. Rockwell believes it is well-positioned to achieve annual revenue of $100M in the next few years.

06:03 EST Westport, Johnson Matthey announce collaboration - Westport Fuel Systems announced their collaboration with Johnson Matthey to develop an emissions aftertreatment system tailored to Westport's proprietary H2 HPDI hydrogen fuel system, with the goal of reducing or eliminating emissions. The agreement focuses on combining Johnson Matthey's technologies and products with Westport's H2 HPDI fuel system to create the lowest possible vehicle tailpipe emissions. In collaboration with Johnson Matthey, Westport will test and develop the Johnson Matthey prototype system at the company's engineering center in Vancouver, Canada.

06:02 EST LL Flooring expects to open three to four new stores in 2023 - LL Flooring provided a business update in advance of investor meetings, noting the company's plans to slow new store openings and recommence share repurchases in 2023 under its existing share repurchase program. "We are confident in our long-term growth strategies and our unique positioning of offering the high-touch service of an independent combined with the value and convenience of a national brand," said President and CEO Charles Tyson. "In light of the current macroeconomic environment, we believe it is prudent to slow our new store opening cadence and allocate capital toward share repurchases under our current authorized plan." The company recently opened two new stores in Bellingham, Washington, and Joplin, Missouri, bringing total new store openings to 18 in 2022. Looking ahead to 2023, the company currently expects to open three to four new stores. The company will continue to evaluate its new store opening strategy based on the operating environment.

05:26 EST Galapagos, CellPoint present initial data from ongoing ATALANTA-1 study - Galapagos and CellPoint presented initial data from the ongoing ATALANTA-1 Phase 1/2 study with GLPG5101 at the 64th Annual American Society of Hematology, or ASH, Congress taking place in New Orleans, Louisiana. ATALANTA-1 is a Phase 1/2 study in heavily pre-treated rrNHL patients to evaluate the safety, efficacy, and feasibility of GLPG5101, a fresh CD19 CAR-T product candidate manufactured at point-of-care. The dose levels that are evaluated in the Phase 1 part of the study are 50x106, 110x106 and 250x106. As of November 8, 9 patients were enrolled; baseline and safety data for eight patients were available. Seven patients reached the follow-up period of 28-days and were eligible for efficacy evaluation. The initial results from seven patients that were eligible for efficacy evaluation indicated that a seven-day vein-to-vein time is feasible and demonstrated strong and consistent in vivo CAR-T expansion levels. Moreover, the initial efficacy results are encouraging with an objective response rate, or ORR, of 86% observed and all responding patients achieving a complete response, or CR. A duration of response of up to seven months has been reported and follow-up is ongoing. Two patients who received DL1 that progressed after initial stable disease or CR respectively, had a CD19-negative escape. No CD19-positive relapses have been observed. In the safety analysis of these seven patients, adverse events were consistent with the known toxicities of CD19 CAR-T treatment. No grade 3 or higher cytokine release syndrome, or CRS, or immune effector cell-associated neurotoxicity syndrome, or ICANS, was observed in any of the patients. At DL2, CRS grade 1 or 2 was reported in 4 patients and ICANS grade 1 was reported in three patients. Patients at DL1 did not experience any grade of CRS or ICANS. Dose-limiting toxicity was observed in 1 patient and the majority of grade 3 adverse events were hematological toxicities.

05:18 EST Equinix to enter South African market with $160M data center investment - Equinix announced plans to enter the South African market with a $160M data center investment in Johannesburg that augments its current footprint on the African continent in Nigeria, Ghana and Cote d'Ivoire. The new data center is expected to open mid-2024. With its South Africa expansion, Equinix is entering one of the largest and most digitally developed nations on the African continent.

05:14 EST Gold Fields CEO Chris Griffith to step down - Gold Fields has announced that Chris Griffith will step down from the board of directors and as CEO of Gold Fields, effective December 31.

05:06 EST ImmunoGen enters exploratory research collaboration with Biosion for ADCs - Biosion announced an exploratory research collaboration to create antibody-drug conjugates, or ADCs, for the treatment of cancer with ImmunoGen (IMGN). In the joint research effort, Biosion will leverage its proprietary SynTracer high-throughput, or HT, endocytosis platform to generate highly selective antibodies to targets allocated by each company and ImmunoGen will provide their proprietary linker-payload technology to create novel ADCs.